Next Article in Journal
An Insight into the Cosmetic and Dermatologic Applications of the Molecules of Palmyra Palm
Previous Article in Journal
Long Term Follow-Up in Gluteal Augmentation Using Cross-Linked Hyaluronic Acid: Up to 20 Months Ultrasound Follow-Up
Previous Article in Special Issue
Liposomes and Ethosomes: Comparative Potential in Enhancing Skin Permeability for Therapeutic and Cosmetic Applications
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Journey Along the Boulevard of Bioactive Compounds from Natural Sources, with Cosmetic and Pharmaceutical Potential: Bee Venom, Cobra Venom, Ficus carica

by
Monica Dinu
1,
Carmen Galea
2,*,
Ana Maria Chirilov
1,*,
Alin Laurențiu Tatu
3,4,5,†,
Lawrence Chukwudi Nwabudike
6,†,
Olimpia Dumitriu Buzia
1 and
Claudia Simona Stefan
1
1
Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, “Dunarea de Jos” University of Galati, 800008 Galati, Romania
2
Department of Medical Disciplines, Faculty of Dental Medicine, University of Targu Mures, 540099 Targu Mures, Romania
3
Clinical Medical Department, Faculty of Medicine and Pharmacy, “Dunarea de Jos” University of Galati, 800008 Galati, Romania
4
Dermatology Department, “Sf. Cuvioasa Parascheva” Clinical Hospital of Infectious Diseases, 800179 Galati, Romania
5
Multidisciplinary Integrative Center for Dermatologic Interface Research MIC-DIR, 800010 Galati, Romania
6
Nicolae Paulescu Institute, 030167 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
These authors contributed equally to the correspondent author.
Cosmetics 2024, 11(6), 195; https://doi.org/10.3390/cosmetics11060195
Submission received: 27 September 2024 / Revised: 13 November 2024 / Accepted: 14 November 2024 / Published: 18 November 2024

Abstract

:
Animal venom and plant extracts have been used since ancient times in traditional medicine worldwide. Natural components, valued for their safety and effectiveness, have been consistently used in cosmetic and pharmaceutical applications. We propose a journey along the boulevard of active compounds from natural sources, where bee venom (BV), cobra venom (CV), and Ficus carica reveal their individual therapeutic and cosmetic properties. The originality of this review lies in exploring the synergy of these bioactive sources, an approach that has not been presented in the literature. Although BV, CV, and Ficus carica have different origins and compositions, they have multiple common pharmacological and cosmetic actions, which make them ideal for inclusion in various products that can be used for skin care and health in general. Their anti-inflammatory, antioxidant, immunomodulatory, antimicrobial, neuroprotective, and regenerative properties give them an essential role in the creation of potential innovative and effective products in the pharmaceutical and cosmetics industry. Although many plant extracts have antioxidant and anti-inflammatory properties, Ficus carica was chosen due to its complex biochemical composition, which provides valuable benefits in skin regeneration and protection against oxidative stress. According to the International Nomenclature of Cosmetic Ingredients (INCI), Ficus carica is used in the form of an extract of fruits, leaves, juice, bark or stem, each having specific applicability in topical formulations; due to the diversity of bioactive compounds, it can amplify the effectiveness of BV and CV, helping to enhance their beneficial effects and reducing the risk of adverse effects, due to its well-tolerated nature. Thus, this combination of natural ingredients opens up new perspectives in the development of innovative products, optimizing efficiency and maintaining a favorable safety profile. In this context, due to the reported experimental results, the three natural sources caught our attention, and we conceived the present work, which is a review made following the analysis of the current progress in the study of the bioactive compounds present in BV, CV, and Ficus carica. We focused on the novelties regarding pharmacological and cosmetic actions presented in the literature, and we highlighted the safety profile, as well as the modern approaches regarding the delivery and transport systems of the active substances from the three natural sources, and we evaluated their prospects in therapeutic and cosmetic use. This paper not only expands our knowledge of bioactive compounds, but it can also generate new ideas and motivations for the research and development of innovative treatments and skincare methods.

1. Introduction

The interest in the use of natural resources in the formulation of various products to be used for the treatment of diseases has increased significantly in recent years. This trend is fueled by a desire to find safer and more effective alternatives to conventional treatments, which often come with unwanted side effects. Plants, insects, snakes, and other natural resources are recognized for their potential to provide biologically active agents, which can contribute to the development of new therapies for various conditions [1].
Animal venom is used by many species for defense, or to capture and digest prey. It is composed of complex mixtures of enzymatic and non-enzymatic components, each having distinct pathophysiological roles [2]. This venom does not contain a single toxin but is a sophisticated chemical cocktail, rich in pharmacologically active substances, such as proteins, peptides, and enzymes, with specific biological functions. In addition, venom also includes non-protein compounds such as carbohydrates, lipids, metal ions, and other substances, some of which have not yet been fully identified [3]. Venom research began with the goal of understanding the structure and functions of these substances, as well as their potential medical applications. Along the way, scientific interest in venom has increased due to the extraordinary complexity, specificity, and effectiveness of its components. Most of the substances in the composition of venoms are peptides that bind with high selectivity and affinity to various biological targets, including membrane receptors, ion channels, enzymes, and hemostatic pathways [4].
The bioactive substances present in natural products are a major resource in the cosmetic and pharmaceutical fields. The interest in products based on plant extracts has increased significantly due to their effectiveness and safety. They are used both in skin care and for the treatment of various dermatological and systemic conditions, having antioxidant, antibacterial, and regenerative properties. Extracts obtained from different parts of plants are rich in active compounds, such as terpenes, saponins, tannins, and vitamins, with positive effects on skin health [5,6,7,8,9].
In the cosmetics industry, there is a clear trend to replace synthetic ingredients with natural alternatives. This trend underlines the importance of identifying bioactive ingredients from the natural environment, especially from plants. The diversity of biological activities that some venoms and plants offer highlights their considerable potential in the development of new cosmetic and dermatological formulations [10].
BV, CV, and Ficus carica caught our attention due to the reported common pharmacological actions, which demonstrate a special potential to be included in the formulation of products for use in the cosmetic and pharmaceutical industries, and the novelty of this review lies in the presentation of the hypothesis of a possible synergy between these bioactive sources, based on the complementarity of the bioactive effects of each ingredient, an approach that has not been presented in the literature.

2. Bee Venom

Bees are flying insects that belong to the order Hymenoptera, suborder Apocrita, and are classified into seven families: Colletidae, Stenotritidae, Andrenidae, Halictidae, Melittidae, Megachilidae, and Apidae. The Apidae family also includes the Apis species, whose venoms are the most characterized, but the most studied from a pharmacological and cosmetic point of view is the Apis mellifera venom, to which we refer in this manuscript [11].
Bee products, especially venom and honey, have been used since ancient times, and their medicinal properties have been mentioned in the Bible and the Qur’an [11]. The therapeutic benefits of BV have a long history, being used as early as 3000 BC in traditional Oriental medicine to treat inflammatory diseases, in ancient Egypt from 4000 BC, and later, in the Greek and Roman historical periods, it was used by Aristotle, Galen, and Hippocrates [12,13]. BV is secreted by the venom gland located in the abdominal cavity of female bees and is used by them to defend themselves against enemies [14]. It is a clear liquid with a bitter taste and a distinct honey-like odor, a slightly acidic pH (4.5–5.5), and a specific gravity of 1.13 [15]. The freshly secreted venom is colorless, and when it dries, it forms a light-yellow powder. In freeze-dried form, after the elimination of the liquid phase, it becomes a light-gray to yellow-gray volatile powder, making it prone to volatilization and crystallization in air [16].
A correct collection method is essential to obtain the highest-quality BV. It is important that the venom is collected without contaminants to preserve its purity and efficacy, and the properties of the final product vary depending on the extraction process used [17]. The venom obtained by the electric-shock method is considered effective and is widely used in clinical applications [18]. After collection, BV undergoes processing to extract the active ingredients intended for medical use. Chromatographic separation and molecular genetic engineering methods are used, which allow the obtaining of specific compounds with distinct therapeutic properties [19].

2.1. Composition

The composition of BV can be influenced by several factors, such as bee species, season, and geographical location, and gives it different actions with potential applications in the cosmetic and pharmaceutical industry. BV consists mainly of water (88%), a variety of peptides, enzymes, and other compounds (lipids, carbohydrates, free amino acids, and minerals). The most important peptides are melittin (a small peptide of 26 amino acids that form pores in membranes), apamin (a neurotoxic peptide that degranulates mast cells), adolapin (a peptide with anti-inflammatory properties), seaplane, and protamine. The enzymes present in BV are phospholipase A2 (it degrades phospholipids in cell membranes), hyaluronidase, phosphatase, and α-glucosidase, and the biogenic amines are histamine and epinephrine [20,21,22]. The main components of BV and their pharmaceutical effects are presented in Table 1.

2.2. Pharmacological Actions

2.2.1. Analgesics

Numerous animal studies have shown that acupuncture with BV has significant anti-inflammatory and analgesic effects. The antinociceptive property is explained by counterirritation, which is the application of harmful stimuli in certain areas of the body leading to an increase in the pain threshold and a reduction in its perceived intensity. However, due to methodological limitations and the small number of clinical trials available, it is too early to draw definitive conclusions. However, the efficacy of BV acupuncture in the treatment of arthritis appears to be promising for future research [29,39].

2.2.2. Anti-Inflammatories

Melittin and apamin from BV have strong anti-inflammatory effects, inhibiting pro-inflammatory cytokines [40] and reducing the inflammatory response [41].
The anti-inflammatory effect has been demonstrated by Apis mellifera venom through studies that have concluded that it may be a potential treatment for rheumatoid arthritis. Administration in various concentrations in murine models has led to a reduction in edema in the paws, as well as a decrease in the arthritis index and inflammatory pain [42]. Moreover, BV has also demonstrated anti-inflammatory effects in the treatment of atopic dermatitis, demonstrating that it can become useful in treating this condition [43].

2.2.3. Antimicrobial

The antimicrobial action of BV has been demonstrated in various in vitro and in vivo experiments against bacteria, viruses, and fungi, with melittin having the ability to destroy the cell membranes of bacteria and viruses [44,45]. Thus, BV and melittin showed broad-spectrum antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, as well as against Escherichia coli, Staphylococcus aureus, and Borrelia burgdorferi [46,47,48,49,50].
BV and its constituents have been reported to exhibit prominent antiviral activities against various viruses, such as Herpes simplex, Enterovirus-71, Coxsackie, and Respiratory syncytial virus [51]. Moreover, it inhibited the entry stages of the hepatitis C virus infection cycle and demonstrated that it may have potential in HIV treatment [52,53].
Research has also proven the antifungal effect of BV against Malassezia furfur, Trichophyton mentagrophytes, Trichophyton rubrum, and Candida albicans [43,54,55]. Scientists’ analyses have also shown that BV also has important antiparasitic effects [56,57].
In addition, the results of studies have shown that melittin and apamin in the composition of BV have shown that they can inhibit the growth of Alternaria alternate and Aspergillus pillows, which are pathogens that grow in the nasal cavity and can cause inflammatory diseases of the upper respiratory tract, proving that the mechanism of action consists of inhibiting the production of chemical mediators, such as interleukin (IL)-6 and IL-8 [29,58].

2.2.4. Neuroprotective

BV has been shown to increase the effectiveness of multiple treatments against neurodegenerative diseases [59]. Apamin from BV has neuroprotective effects and can stimulate cognitive function by acting on potassium channels, and melittin exerts antioxidant and neuroprotective actions against neuronal oxidative stress and can be a potential therapeutic agent for neurodegenerative disorders [28,60]. It is also worth noting that improvements in motor symptoms of Parkinson’s have been reported following the administration of BV through acupuncture [61].

2.2.5. Antioxidant

The components of BV, especially melittin, have demonstrated antioxidant effects by reducing oxidative stress at the cellular level [62,63]. Also, Amwaprin, a newly identified protein in BV-inhibited cell growth, oxidative-stress-induced cytotoxicity, and inflammatory response in mammalian NIH-3T3 cells, reduced caspase-3 activity during oxidative stress, and provided protective activity against oxidative-stress-induced cell apoptosis in insect NIH-3T3 and Sf9 cells. The exertion of this protective effect against oxidative stress is due to its direct interaction with the cell membrane. At the same time, Amwaprin demonstrated free radical neutralization activity and protected DNA against oxidative damage. These findings suggest that its antioxidant properties are the result of synergy between its ability to scavenge free radicals and cell protection, highlighting an important role as an antioxidant agent [64].

2.2.6. Immunomodulators

BV has been shown to boost the immune system, particularly by activating T cells and macrophages and modulating the immune response, which may be beneficial in the treatment of autoimmune and inflammatory diseases [65,66].

2.2.7. Anti COVID-19

Through the proven pharmacological actions of strong antiviral, anti-inflammatory, and immunomodulatory, it can be suggested that BV treatment could be a potential complementary therapy for the prevention of severe acute respiratory syndrome—coronavirus 2 (SARS-CoV-2) [67,68,69].

3. Cobra Venom

Snakes are reptiles of the order Squamata and are part of the suborder Serpentes. They are found on all continents except Antarctica, and to date number about 3900 species. Their venoms are among the most complex of animal venoms, and the families most intensively studied in this regard are Viperidae, Crotalidae, and Elapidae [70,71]. The snakes of the family Elapidae are cobra, coral snakes, kraits, and mamba, and are known for their neurotoxic effects, which in most cases cause paralysis [72]. Cobra is a name that represents a group of venomous snakes that are part of the Elapidae family, and of this group, of pharmacological interest are the venom of the genus Naja (Naja kaouthia, Naja sumatrana, Naja pallid, Naja naja atra) and the genus Ophiophagus Hannah (king cobra) [70,71,72]
Snake venoms have been used to treat various ailments for thousands of years, especially in traditional Chinese medicine to treat opium addiction, and Indians have used it to treat pain by combining it with opium [73]. Starting with the second half of the twentieth century, due to advances in analytical techniques, snake venom began to be of increasing interest to researchers due to the identification of a rich content of molecules with pharmaceutical and cosmetic potential [74].
The pharmaceutical industry has produced several venom-derived drugs: Captopril (the first product to appear, approved by the Food and Drug Administration in 1981), Aggrastat, and Eptifibatide, all designed based on the components of snake venom [75,76]. Ximelagatran, a drug made by CV specialists, was a thrombin-inhibiting anticoagulant that was used as a blood thinner and direct thrombin inhibitor, but due to the appearance of hepatotoxicity reactions, the research stopped, and it was withdrawn from countries where it was already authorized [77].
CV is a pale-yellow viscous liquid that contains a complex mixture of bioactive substances, each of which has a specific role in capturing prey, acting together to immobilize prey and induce rapid and destructive toxic effects. Its composition can be influenced by factors such as habitat, diet, sex, and ontogenetic development [78]. To be used in various research, the venom is collected by milking, then to remove any impurities it is filtered through 0.45 μm filters, and subsequently, it is freeze-dried and stored at -20 °C until use [79].

3.1. Composition

The main components of CV are neurotoxins(low molecular weight peptides belonging to the three-finger protein family, including some alpha-neurotoxins, which can have a high selectivity for nicotinic acetylcholine receptors), cardiotoxins(polypeptides that affect heart muscle cells), phospholipase A2 (PLA 2), cobra venom factor (CVF), nerve growth factor (NGF), L-amino acid oxidase (LAAO), acetylcholinesterase, and many other substances [80,81]. The main components of BV and their pharmaceutical effects are presented in Table 2.

3.2. Pharmacological Actions

Despite its toxicity, CV has demonstrated through various studies, a high degree of therapeutic potential through various actions:

3.2.1. Analgesics

Many studies have shown that CV has played an important role in relieving pain (cancer pain, neuralgia, arthralgia), having the ability to block essential components of the pain signaling system, especially ion channels [82,83,98]. Cobrotoxin or cobratide (a short-chain postsynaptic α-neurotoxin isolated from the venom of the snake, Naja atra) was approved in 1998 in combination with synthetic drugs as an analgesic for the treatment of moderate to severe pain [2,98]. It has also been shown to become a substitute for morphine, suppressing withdrawal symptoms caused by its use [99,100].

3.2.2. Anti-Inflammatories

CV has neurotoxic and enzymatic components that have anti-inflammatory effects, modulating the immune response and reducing inflammation in various experimental models. Cobrotoxin, cardiotoxin, and neurotoxin extracted from Naja naja atra venom have shown anti-inflammatory properties, acting by decreasing TNF-α and IL-1β levels, as well as reducing the enzymatic activities of myeloperoxidase (MPO) and iNOS [84,101]. These research-proven anti-inflammatory effects recommend CV as a potential candidate for the treatment of chronic inflammatory diseases [102,103].

3.2.3. Antioxidant

Although CV is best known for its toxic effects, some peptides and enzymes may help reduce oxidative stress through indirect mechanisms, such as modulating the immune response. CVF, isolated from Naja naja, has an activating effect on the complement system and has been used for studying the complement cascade, and the oxygen extracted from Naja oxiana venom has been shown to inhibit the formation of C3 convertase by blocking the classical complement pathway. These results highlight the potential of cobra venom in the development of inhibitory drugs, which are essential in combating various conditions, including autoimmune diseases [104].

3.2.4. Antimicrobial

CV contains enzymes and peptides with antimicrobial potential, which can inhibit the growth of bacteria and other pathogens, helping to reduce the risk of infections. Researchers reported that α-neurotoxins inhibited the replication and toxicity of several viruses both in vitro and in vivo [86,105]. The antibacterial effects of CV have been reported against numerous strains, including Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli [106].

3.2.5. Neuroprotectants

The researchers found that a secretory phospholipase A2 from the venom of the snake Naja sumatrana helps cells survive under oxidative stress. The A2-EPTX-NSm1a protein has been shown to protect neurons from oxidative stress damage by stopping apoptosis and altering protein expression related to neuronal inflammation and apoptosis. Thus, the possibility of using A2-EPTX-NSm1a or other proteins from the venom of the snake Naja sumatrana in drug discovery or for research into neurodegenerative diseases caused by oxidative stress is suggested [90].

3.2.6. Immunomodulators

CV has demonstrated immune system modulation activity by inhibiting excessive immune responses, making it useful in treating inflammatory or autoimmune conditions [107].

3.2.7. Anti COVID-19

Naja atra venom and cobrotoxin have been shown to inhibit lung inflammation, improve pulmonary gas exchange function, and attenuate the development of fibrotic lesions in the lungs, thus becoming potential therapeutic agents to treat COVID-19 patients [108,109,110].

3.2.8. Anticancer

The anticancer activities of CV represent one of the most promising therapeutic characteristics and have been intensively researched and reviewed in recent years, with the results proving that the CV causes irreversible changes in the cell, destroying it completely. In in vivo studies, Naja nigricollis venom has been shown to inhibit the growth of melanoma by such a mechanism. The cytotoxins CT1 and CT2 from Naja oxiana, CT3 from Naja kaouthia, and CT1 from Naja haje have also been shown to have this ability against human lung adenocarcinoma A549 and promyelocytic leukemia cells HL60 [111].
Cytotoxins isolated from the venom of the snake, Naja oxiana, demonstrated superior anticancer activity compared to cisplatin (a drug used in the treatment of cancer). Studies have shown that these toxins have minimal impact on normal cells and induce apoptosis in various cancer cell lines (HepG2, MCF-7, HL-60, and DU-145) via the lysosomal pathway and by releasing cathepsins into the cytosol [112].
Furthermore, one study showed that the venom of the Moroccan cobra Naja haje, in particular the F7 fraction obtained by gel filtration chromatography, demonstrated the strongest effect against hepatocellular carcinoma, an action associated with reduced toxicity compared to normal hepatocytes [113].

3.2.9. Other Pharmaceutical Effects of CV

Studies have reported that CV has also demonstrated protective effects on adriamycin-triggered nephrotic syndrome in rats, effects to improve lung gas exchange function and attenuate fibrotic lesions in the lungs, as well as beneficial effects in systemic lupus erythematosus [114,115,116,117].

4. Ficus carica

Figs are among the first plants cultivated by humans over 11,000 years ago [118,119]. The history of figs has its roots in the time of the Roman Empire, and their cultural and religious importance is also mentioned in sacred writings such as the Bible and the Qur’an [120]. The fig tree has been recognized since ancient times for its therapeutic benefits in treating various dermatological problems. In the fourteenth century, historical writings highlighted the knowledge of its healing properties, influenced by the studies of Dioscorides and Galenus of Pergamon [121,122,123].
The genus Ficus, part of the Moraceae family, includes about 850 species spread globally, making it one of the most extensive genera of angiosperms. Ficus carica is a small, deciduous tree, recognized as one of the largest genera of angiosperm plants, and it is a heterozygous species, popularly known as a “fig”. This tree has small, green, pedunculate flowers, which are hidden inside a fleshy receptacle, not visible from the outside; only the fruit are observable, and all the flowers are female and self-pollinating, a phenomenon characteristic of figs [122,124].

4.1. Composition

Ficus carica is a rich source of minerals, carbohydrates, vitamins, sugars, dietary fiber, organic acids, and phenolic compounds. Fig fruits, leaves, and latex have various components with anti-inflammatory action. Phytochemical analyses revealed the presence of alkaloids, tannins, glycosides, flavonoids, saponins, coumarins, phenols, sterols, terpenes, carbohydrates, and proteins in the fruit [125]. The fruits and leaves contain coumarins and flavonoids, compounds that are known for their antioxidants, anticancer, and anti-inflammatory effects [126,127]. There are 34 known flavonoids in Ficus carica leaves, and they have various properties, routine being very important from a pharmacological point of view, and having antidiabetic and antioxidant effects [128,129]. Ficus carica leaves contain six types of coumarins, which are associated with antioxidant, antibacterial, and antidiabetic activities, with umbelliferone being the most present coumarin [130,131]. Studies have found that the bark and fruits of Ficus carica contain 15 anthocyanin pigments, most of which contain cyanidin and pelargonidin derivatives [132].
Fig fruits were evaluated in a study that included six different varieties and varied colors (black, red, yellow, and green), for the content of total polyphenols, total flavonoids, and antioxidant properties. They exhibited the highest levels of antioxidant compounds, having the highest antioxidant capacity [133,134].
Total and individual phenolic compounds such as phenolic acid, chlorogenic acid, and flavonoids have been identified from fresh and dried fig peels. The amounts of phenolic substances were higher in dried figs due to the increased concentration in the dried peel [135]. Specialists have identified, following the specific analyses carried out, four free sugars (glucose, fructose, trehalose, and sucrose) and five organic acids (oxalic, quinic, malic, citric, and succinic) in the peel and pulp of a variety of figs from Portugal [136]. Polyphenols and carotenoids are two essential groups of phytochemicals present in figs, reflecting a diverse and valuable chemical composition. Among the major polyphenols are phenolic acids, flavones, flavanones, flavonols, anthocyanins, and proanthocyanidins, which contribute significantly to the antioxidant activity of figs. The high levels of phenolic compounds even exceed the concentrations found in red wine and tea, two of the most well-known sources of polyphenols [137]. In addition, anthocyanin-rich varieties of figs have a concentration comparable to that of blackberries and blueberries, thus highlighting their nutritional and antioxidant potential [135]. An evaluation of the different parts of figs (leaves, peel, and pulp) underlined the superiority of the leaves in terms of total polyphenol content and antioxidant capacity. Fig leaves stand out for these exceptional properties, considerably surpassing both the peel and the pulp in these aspects. This particular leaf quality gives them significant potential for nutritional and therapeutic uses [138,139].
Another important component of Ficus carica is psoralen, which is used in the treatment of skin diseases and is approved by the FDA as part of PUVA (Psoralene and ultraviolet A) therapy, making it effective for conditions such as eczema, psoriasis, and vitiligo, when combined with UV-A radiation [140]. Along with other natural remedies, such as piperine [141], psoralen is a photosensitizing substance used in the PUVA-therapy P from the application, or the internal administration of psoralene, followed by exposure to ultraviolet light in the treatment of vitiligo [142].
Figs also stand out as a valuable source of numerous micronutrients and macronutrients, including carbohydrates, essential vitamins, organic acids, dietary fiber, and minerals. This rich nutritional composition underlines their beneficial potential for health and their importance to a balanced diet [143].

4.2. Pharmacological Actions

The fig tree is recognized for its therapeutic potential in treating a variety of conditions, including diabetes, liver disease, asthma, ulcers, skin infections, gonorrhea, infections and disorders of the digestive, endocrine, reproductive, respiratory, gastrointestinal, and urinary systems [124,144]. The leaves are used as protection from the sun and as a chemoprotective agent. The fruits and leaves have anti-cancer and anti-acne properties: latex helps reduce viral titers, and the roots are useful in treating ringworm. Virtually all components of the Ficus carica plant have been documented with medical benefits, including anticancer activity against various cancers [124,145,146]. In the same context, fig extract seems to have applicability in the treatment of cardiovascular diseases due to its content of flavone, rutin, and quercetin [147].

4.2.1. Anticancer

The antitumor mechanisms of Ficus carica include the induction of apoptosis in tumor cells by decreasing Bcl-2 expression, the activation of caspases 3 and 9, the increase in pro-apoptotic markers Bax and PARP, facilitating programmed cell death [124,146].
Research has highlighted the viability of fig-leaf extracts in the prevention and treatment of cervical melanoma, due to compounds such as bergapten and psoralene, which demonstrate anticancer properties [148,149].

4.2.2. Antioxidant

The antioxidant activity of Ficus carica fruit extract was rated at 87%. Ficus carica is rich in two main categories of phenolic compounds: phenolic acids (such as gallic acid, chlorogenic acid, and syringic acid) and flavonoids (including catechin, epicatechin, and anthocyanins). These phenolic compounds are considered among the most effective natural antioxidants [150]. The antioxidant mechanism of Ficus carica is evidenced by the reduction of oxidative stress, which helps to combat organ toxicity by decreasing oxidation markers (MDA) and increasing the levels of antioxidants such as GSH, SOD and catalase, with this action restoring the functions of various organs, facilitating histological reconstruction and protecting cells from oxidative damage [124,144,150].

4.2.3. Hepatoprotective

An extract of petroleum ether from fig leaves was investigated for hepatoprotective activity in rats orally treated with 50 mg/kg rifampicin, and the significant reversal of the biochemical, histological, and functional changes caused by rifampicin suggested possible hepatoprotective activity [151].

4.2.4. Antibacterial and Antifungal

Ficus carica methanolic extract has demonstrated strong antibacterial activity against oral bacteria. The combined effects of methanolic extract with ampicillin or gentamicin had a synergistic effect against these bacteria, suggesting that figs could function as a natural antibacterial agent [152].
The extracts of hexane, chloroform, ethyl acetate, and methanol from Ficus carica latex were evaluated in vitro for their antimicrobial activity against five species of bacteria and seven strains of fungi, using the disk diffusion method. The methanolic fraction demonstrated complete inhibition against Candida albicans (100%) at a concentration of 500 μg/mL and had a bactericidal effect against Cryptococcus neoformanstag. Also, the methanolic extract (75%) showed significant inhibition of Microsporum canis, and the ethyl acetate extract showed strong activity at a concentration of 750 μg/mL [153].

4.2.5. Hypoglycemic

The leaf extract was found to produce a significant hypoglycemic effect when administered orally or intraperitoneally to diabetic rats treated with streptozotocin. Weight loss was prevented in treated diabetic rats, and plasma insulin levels greatly influenced the survival rate. The results obtained suggest that the aqueous fig extract has a notable hypoglycemic activity [154].

5. The Potential Uses of BV, CV, and Ficus carica in Skin Care and Treatment Products

As the most exposed organ of the body, the skin is vulnerable to numerous environmental factors, including variations in temperature, solar radiation, cigarette smoke, and ozone and chemical pollutants. These are all included in the concept of the “exposure”. This represents the set of influences to which a person is subjected from birth to the end of life and is a relatively new term [155,156]. Psychological stress manifests itself when external demands exceed a person’s adaptive resources, triggering changes at the emotional, behavioral, and physiological levels [157].
Oxidative stress in the skin is directly related to the appearance of age spots. The oxidation of lipids and proteins leads to the accumulation of lipofuscin, which, along with melanin, contributes to dark spots that are difficult to degrade by hydrolytic enzymes [158]. Oxidative and inflammatory processes stimulate the production of neutrophil elastase and metalloproteinase-8 (MMP-8), which contribute to the degradation of collagen and elastic fibers, thus favoring the appearance of wrinkles [159]. Preventing signs of aging, such as dry skin, loss of firmness and elasticity, or wrinkles, is a major challenge. Aging brings visible changes in the epidermis, dermis, and subcutaneous tissue. At the level of the epidermis, there are the thinning of the layers, the flattening of the dermal-epidermal junction, the reduction in natural hydration, the decrease in lipids and their oxidation, and increased transepidermal water loss (TEWL). In the dermis, the following are observed: the reduction of fibroblasts and the production of collagen and elastin, fiber degradation, and the loss of skin elasticity, associated with a decrease in hyaluronic acid [160,161].
Over time, research into anti-aging solutions has constantly evolved. The bioactive substances in moisturizers support the skin barrier and reduce skin damage through hydration and lipid protection [155]. Anti-aging ingredients inhibit enzymes that degrade collagen and elastin. Products with natural ingredients are popular for caring for dry and mature skin, improving hydration, and protecting skin structure, but their effectiveness in vivo requires further research [160,162,163].

5.1. BV—Beneficial Actions for the Skin

BV has been studied and found to be used in the treatment of various skin conditions, including atopic dermatitis, acne vulgaris, alopecia, morphea, melanoma, vitiligo, psoriasis, and for wound healing, but it is also widely used in cosmetics in the form of topical preparations [164] (Figure 1).
Thus, BV is included as an active ingredient in various cosmetic products such as face creams, balms, masks, and serums, and is used due to its astringent, anti-inflammatory, anti-aging, and antibacterial properties [165,166,167].

5.1.1. Healing and Regenerative Properties

BV has been shown to stimulate tissue regeneration and wound healing, being used in various formulations to improve the healing process [168]. Amen et al. studied a wound dressing with a content of 4% BV, 10% polyvinyl alcohol, and 0.6% chitosan on diabetic rat models, which, after application, demonstrated an improvement in wound healing, and also an anti-inflammatory effect like other natural preparations [169,170].
Another group of researchers focused on developing a hydrogel-based on PVA (polyvinyl alcohol) and chitosan (promising excipient for retard dosage forms) [171], with BV incorporated. The study showed that the integration of BV significantly improved the morphological, physical, and mechanical properties of the hydrogel. In addition, the antioxidant and anti-inflammatory activities of this formulation accelerated the wound healing process, especially in skin regeneration in patients with diabetes. The use of topical preparations reduced systemic side effects, suggesting that hydrogel-based formulations may provide good patient compliance due to their safety and efficacy profile [172].
The results of research on mice concluded that the use of BV significantly increased wound closure in diabetic animal models by improving collagen production and restoring the inflammatory cytokines TGF-β and VEGF [173].

5.1.2. Anti-Inflammatory and Soothing Properties

BV can reduce redness and inflammation, making it beneficial for sensitive or irritated skin from various dermatological conditions.
Acne
Currently, there are numerous studies demonstrating the effectiveness of BV in the treatment of acne: A double-blind randomized control trial was conducted by Han et al. on 12 subjects for 14 days to observe the effects of purified BV in this condition. The mechanism was examined by scanning electron microscopy and transmission electron microscopy. It was found that participants who used products containing BV had a 57.5% reduction in ATP (adenosine triphosphate) levels. There was a significant difference in gradation levels based on the number of inflammatory and non-inflammatory lesions in favor of subjects treated with venom compared to the control group. Researchers have also observed and reported that BV has concentration-dependent antimicrobial activity [174].
Another prospective, non-comparative study was conducted by Han et al. on 30 acne subjects who used a purified serum (purified BV diluted in cold sterile water) twice daily for 6 weeks. A clinical evaluation of the lesions was performed at weeks 0, 3, and 6, with a percentage improvement in acne of 52.3% after 6 weeks. Marked therapeutic effects were obtained, and 77% of the volunteers showed a visual improvement at the end of the research [175].
An et al. studied the effects of BV on skin inflammation caused by Propionibacterium acnes (responsible for the appearance of inflammation in acne). P. acnes was injected intradermally into the ears of mice and BV (in concentrations of 1, 10, and 100 μg, mixed with 0.05 g of petroleum jelly) was applied only to the right ear. A decrease in inflammatory cell infiltration and a reduction in IL-1β and TNF-α have been observed in the ear treated with BV [176].
Lee et al. studied the therapeutic effects of melittin on P. acnes-induced inflammation. The thickness of the ears of mice injected with melittin showed a 1.3-fold reduction compared to those in which P. acnes alone was injected and significantly decreased the expression in TNF-α and IL-1β, the results demonstrating that melittin has the potential to be used as an alternative treatment in inflammatory skin diseases caused by P. acnes [177].
Atopic dermatitis
The anti-inflammatory effect of BV has also been demonstrated in the treatment of atopic dermatitis. Patients who used emollient topically with BV had a lower eczema area, severity index, and visual analog scale value than patients who used emollient without BV [43].
The anti-inflammatory activity of apamin has been investigated in the context of TNF-α- and IFN-γ-induced inflammatory responses in human keratinocytes, specific to atopic dermatitis. The results indicate that apamin has a significant role in atopic dermatitis due to its anti-inflammatory properties [178].
Vitiligo
BV has been shown in an in vitro study to stimulate melanocyte proliferation in a dose-dependent manner at concentrations of 10 μg/mL or higher for 7 days, resulting in an approximately two-fold increase in melanocyte counts compared to the control group. Research results suggest that BV may be a potential ingredient in various formulations designed to treat vitiligo [179].
Psoriasis
BV has the potential to become a new therapy for localized plaque psoriasis. Administered intradermally either alone or in combination with oral propolis, BV has proven to be an effective treatment for this condition. BV decreases the levels of IL-1β, TNF-α, and IL-6, due to the presence of melittin, which inhibits the expression of inflammatory genes. Venom also reduces COX-2 expression, thereby decreasing the production of prostaglandins involved in inflammation [180].
In a randomized double-blind clinical trial, 25 patients aged 18 to 60 years who suffered from recalcitrant localized plaque psoriasis (RLPP) were treated with BV. Treatment was administered once a week for 3 months, starting with a dose of 0.05–0.1 mL, which gradually increased to 1 mL per injection. A complete response was observed in 92% of the patients treated with BV. The side effects were minor, including erythema, moderate pain, and mild swelling at the injection site, all of which were manageable [181].

5.1.3. Anti-Aging/Anti-Wrinkle Properties

BV stimulates the synthesis of collagen and elastin, improving skin firmness and elasticity and reducing wrinkles, making it particularly suitable as an ingredient in mature skincare formulas. Often compared to the effects of botox, this substance influences the mechanisms of cutaneous neurotransmission, relaxing the muscles responsible for facial expressions [182].
The first clinical trial investigating the effect of cosmetics containing BV on human facial wrinkles was led by Han and his collaborators. In this study, 22 South Korean women, aged 30 to 49, applied a facial serum with a concentration of 0.006% BV, using 4 mL of the product twice a day for 12 weeks. The wrinkle changes were assessed by visual examinations by a dermatologist, by analyzing photographs, and by imaging analysis of skin replicas. The results indicated a clinical improvement in facial wrinkles, evidenced by reducing the total surface area, number, and average depth of wrinkles, without causing side effects. Thus, the serum containing BV is effective and safe for reducing wrinkles [183].
A clinical evaluation of the efficacy of a face cream containing BV involved 30 volunteers selected after an irritation test and exclusion criteria. BV was added as an active ingredient and the melittin content was previously measured. Skin condition was assessed at 14 and 28 days, using specific indices and a 9-point scale for 15 skin attributes. During the 28 days of care, improvements were observed in the superficial layers of the skin, consistent with the volunteers’ tolerance and satisfaction assessments. Good tolerance and high satisfaction suggest the potential for long-term continued application, with possible anti-aging effects. The study concluded that BV is an effective active ingredient that, after 14 days of use, demonstrated visible improvements in skin condition, with the potential for better results through extensive use [184].
A group of researchers obtained PLA2-free bee venom (PBV) by removing PLA2 using ultrafiltration of natural bee venom and evaluated its effectiveness as an ingredient in skincare products compared to the original BV. They then investigated its potential cosmetic properties, focusing on its benefits (anti-wrinkle effect) as well as possible adverse effects (cytotoxicity). The results showed that both BV and PBV restore cellular integrity, stimulate collagen production, and inhibit the activity of MMP-1 and -13 in HaCaT cells, as well as MMP-1, -2, and -3 in UVB-exposed HDF cells. However, BV has an adverse cytotoxic effect, while PBV could offer advantages in preventing wrinkle formation without inducing cytotoxicity. Thus, the use of PBV in cosmetics appears to be a promising strategy for preventing wrinkles and protecting the skin from UVB exposure [185].

5.1.4. Moisturizing and Regenerating Properties of the Skin

BV has been shown to contribute to skin regeneration and improved skin texture. A group of researchers formulated a skincare prototype with a content of 0.1% BV, 0.3% propolis extract, 0.45% honey, and 1.0% royal jelly. The prototype body cream was analyzed for stability, activity, antioxidant, dermatological response, and cytotoxicity. The results showed stability at room temperature and +40 °C for up to 90 days, a high antioxidant capacity (85.45%), a lack of cytotoxicity, and an absence of irritation or side effects. The prototype was observed to brighten and moisturize the skin, reduce the visibility of wrinkles, and improve skin elasticity [186].

5.1.5. Hair Growth Stimulating Properties

BV demonstrated significant potential in stimulating hair growth, according to a study in which various concentrations of BV (0.001%, 0.005%, and 0.01%) were used, compared to the effects of applying 2% minoxidil [187].

5.2. CV- Beneficial Actions for the Skin

One of the compounds commonly used in cosmetic products is bioactive peptides, which comprises chains of amino acids with specific sequences that give them biologically active properties, capable of influencing various functions of the body. Even in low concentrations, these peptides can exert a wide range of activities, including moisturizing, antibacterial action, and regenerating or nourishing the skin. The effectiveness of peptides is directly related to their amino acid sequence [188]. Proteins and peptides derived from natural sources are particularly appreciated, being extracted from both animal and plant sources. For example, animal-derived peptides can be obtained from BV or snake venom [189]. Peptides in snake venom have demonstrated anti-aging properties and are protected by patents, an example being snake venom-derived pentapeptide-3 (GPRPA) which has demonstrated a reduction in wrinkles and skin roughness [190].

Healing and Regenerative Properties

CV in small and controlled doses can promote tissue regeneration through its effects on cells and blood vessels, promoting healing and proving that it can be a potential ingredient in various pharmaceutical and cosmetic formulations with beneficial effects on the skin [191] (Figure 2).

5.3. Ficus carica—Beneficial Actions for the Skin

Plant extracts and phytochemical compounds with antioxidant, anti-inflammatory, and immunomodulatory properties play an essential role in skin protection. They can neutralize free radicals, stimulate antioxidant enzymes such as catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GSH-PX), and reduce inflammation by regulating cytokines and inhibiting pro-inflammatory enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) [192,193,194]. Traditional medicine has mainly focused on the use of figs to treat dermatological problems [149]. Clinical studies have shown that extracts from Ficus carica improve skin hydration, reduce transepidermal water loss, and normalize sebum production, thus contributing to maintaining skin health under conditions of psychological stress [195]. The main constituents of fig and their effects on the skin are presented in Table 3.

5.3.1. Anti-Aging/Anti-Wrinkle Properties

Ficus carica has significant potential in the field of cosmetics, especially due to its content of ficin and phenolic compounds. These substances help protect skin cells against oxidative stress caused by psychological stress. Ficus carica extract is effective in reducing oxidative damage to lipids and proteins, thereby protecting skin integrity and preventing premature aging [202].
Ficin, a proteolytic enzyme, plays a key role in the antioxidant activity of the extract, especially at normal skin pH (4.5–5.0), reducing the markers of oxidative stress such as lipid peroxides and carbonyl proteins [200,201].
A study conducted by researchers demonstrated that water-soluble extract from Ficus carica cultures (FcHEx) has significant antioxidant and anti-inflammatory properties, protecting the skin from oxidative damage caused by psychological stress. By reducing oxidative stress, inflammation, and transepidermal water loss, FcHEx helped restore the skin barrier, regulate sebum production, and maintain optimal skin pH. Clinical trials have confirmed the effectiveness of the extract in improving the health and appearance of the skin under stress, preventing collagen degradation, the appearance of wrinkles, and skin color changes. These results suggest that FcHEx has considerable potential to be integrated into skincare products, especially for dry and stressed skin [205].
Plant extracts rich in compounds such as flavonoids, phenolic acids, tocopherols, alkaloids, and monoterpenes, recognized for their antioxidant and anti-inflammatory properties, are commonly used in the development of topical cosmetics [206]. Studies show that blends of plant extracts offer superior efficacy in herbal medicine compared to products containing single extracts [207]. A group of researchers evaluated the antioxidant, anti-collagenase (in vitro) and anti-wrinkle (in vivo) properties of a formulation combining the extracts of Ginkgo biloba, Punica granatum, Ficus carica, and Morus alba [208].
Ginkgo biloba (Ginkgoaceae family), known for its flavonoids and terpenoids, was chosen for its demonstrated photoprotective effects [209]. The fruit extract of Punica granatum (Punicaceae family) was selected because it is used extensively in cosmetics and therapy for protection against UV damage and inhibition of matrix metalloproteinases, thus preventing collagen degradation [210,211]. The other two products in the formulation were Ficus carica (due to the content of phenolics and organic acids that contribute to antioxidant and anti-inflammatory protection), and Morus alba (Moraceae family) which is distinguished by its content of polyphenols and flavonoids, having antioxidant and antimicrobial effects [212,213,214]. Collagenase is a metalloproteinase that breaks down essential proteins such as collagen and elastin, and inhibiting this enzyme can help maintain the integrity of the dermal matrix and prevent skin degradation [215]. The randomized, open-label, simple-blind, placebo-controlled, observer-blind study was conducted on 21 women aged 45 to 65 years. Participants applied twice a day, for 56 days, a cream with 2% fruit extract on one side of the face and on the other side a placebo. After 28 days, no significant differences were observed, but at the end of the 56 days there was a significant decrease in the depth, length, and surface of the wrinkles on the treated side. Antioxidant tests evaluated the ability to capture free radicals (DPPH, H2O2, and O2⁻), and the extracts showed strong antioxidant activity, comparable to or above reference standards. The inhibition of oxygen radicals has also been shown to be dose-dependent. Anti-collagenase activity was measured by in vitro inhibition of the collagenase enzyme, with significant results at a concentration of 5 μg/mL (67.45% inhibition) and variable effects at lower doses (between 12.03% and 55.61%). The results showed that the synergistic formula of these plant extracts provides significant protection against collagen degradation and oxidative stress, while also having a notable impact on reducing wrinkles on human skin [208].

5.3.2. Anti-Inflammatory and Soothing Properties

The phenolic compounds in Ficus carica help reduce inflammation and improve skin-barrier function by inhibiting pro-inflammatory cytokines, such as interleukin-6, and reducing the effects of stress hormones, such as epinephrine. They have gained popularity in skin care due to their properties to combat dryness, eczema, and acne, neutralize free radicals, prevent aging, and protect the skin [216,217]. Myricetin, quercetin, kampferol, gallic acid, syringic acid, and rutin are substances detected in Ficus carica that can inhibit the activity of the enzyme 5-alpha-reductase, resulting in a reduction in sebum levels when applied [197].
Khan et al. aimed to evaluate the effects of a cream containing Ficus carica L. fruit extract on various skin features, including melanin, erythema, hydration levels, transepidermal water loss, and sebum production. For this research, a formulation was designed with a concentrated extract of 4% of Ficus carica fruits, along with an extract-free base, used as a control. Both products were applied to the cheeks of male volunteers for 8 weeks twice a day, using non-invasive bioengineering tools to analyze the impact on different skin parameters. These included the Mexameter reflection spectrophotometer for measuring melanin and erythema, the Tewameter MPA 5 timer for analyzing water loss from the dermis and the water content of the stratum corneum, and the MPA 5 sebometer for assessing sebum secretion. To test a possible irritative action, patches were applied to both forearms of the participants, each having either the base or the forms, and after 48 h, a specialist doctor analyzed the presence of irritations. After applying the base, minor oscillations in melanin levels were observed, while the use of the extract demonstrated a steady decrease in melanin content, due to the action of substances that inhibit the activity of tyrosinase, known for their depigmenting activity. Analyses have shown that the antioxidants and vitamin C in fig extract help reduce transepidermal water loss and stimulate collagen synthesis. A significant decrease in sebum production has also been observed, indicating that a stable local cream containing F. carica fruit extract may have anti-wrinkle and anti-acne potential [150].
Research has also focused on the benefits of fig extracts in other skin conditions: relieving the symptoms of atopic dermatitis (suggesting that they may be an alternative to corticosteroids), melasma (as an alternative to hydroquinone in topical preparations), psoriasis, and wound healing [164]. It has also been shown that the juice obtained from fig leaves can be beneficial in vitiligo due to the presence of furanocoumarins such as psoralen and daidzein [218].

5.3.3. Skin Moisturizing Properties

Fig fruits are an important source of ascorbic acid (vitamin C), recognized for their role in stimulating and accelerating collagen synthesis in the dermis, and by increasing collagen production, the hydration of the dermis is improved [203]. The fruits also contain phenolic compounds and flavonoids that can reduce skin melanosis by inhibiting tyrosinase, a key enzyme in melanin synthesis. These properties make Ficus carica fruit extract useful in skin depigmentation and moisturizing products. Additionally, fig fruit extract has demonstrated a significant reduction in transepidermal water loss and an increase in hydration, making it a promising ingredient for skincare products [150]. Research results highlight the potential of Ficus carica extract as an essential natural ingredient in skin treatment, protection, and regeneration products, with possibilities for use in various conditions [219,220] (Figure 3).

6. Safety Profile

Looking back at ancient times, we discover that some of the natural ingredients are still used today, and this shows us the importance of rigorous testing for their efficacy and toxicity, as not all natural ingredients are automatically safe [221,222,223].
The use of venom or venom-derived products always carries a risk, as they can cause severe side effects. These products contain extremely potent toxins or modified molecules derived from venom toxins, which can alter normal physiological functions. Compared to raw venom, toxicological studies and evaluations of side effects are relatively less complex for isolated or modified toxins [224].

6.1. BV—Safety Profile

BV therapy can be administered in the following various ways: by direct puncture at specific points, injections with pure and sterile homeopathic preparations, using ointments, gels, creams, lotions, capsules, drops, as well as intravaginal suppositories containing BV [225]. BV is considered an alternative to synthetic topical treatments but can sometimes cause allergic and anaphylactic reactions depending on the dose administered and the individual immune system, so clinical application is limited [226].
It has been found that an average of 140–150 μg of venom is delivered by a bee sting, and the average lethal dose (LD50) of bee venom is between 2.8 and 3.5 mg of venom per kg of human body weight [19,227]. The occurrence of allergic reactions is the main challenge to the approval and routine use of BV. Hypersensitivity to venom can lead to a severe systemic allergic reaction, which can sometimes be fatal [228]. Phospholipase is the main allergen, and implicitly, the most toxic component of bee venom. It acts aggressively on the cell membrane, causing cytolysis. This effect is amplified by the presence of melittin and lysolecitin, which are generated by the action of phospholipase [30]. Studies have shown that BV is dual, with compounds such as amine and melittin providing anti-inflammatory and analgesic properties, but which can also cause irritation and allergic reactions in sensitized individuals [226]. Topical administration of BV is well-tolerated in human skin, as it has shown no risk of dermal irritation in animal studies [229].
To assess the skin tolerance of cosmetic products with BV, a patch test was performed on volunteers under medical supervision. A 0.1 mL BV solution at a concentration of 0.001% was applied to a 1 cm2 piece of filter paper, placed on the volunteer’s forearm and fixed with a hypoallergenic occlusive tape. The patch was maintained for 48 h, after which it was removed, and the area was evaluated after 30 min and then at 96 h (according to current guidelines, the evaluation of adverse reactions is performed at 48 h and 72 h, and if any adverse reaction occurs, an additional evaluation is performed at 96 h) [184].
To minimize adverse effects, research is currently underway to discover safer practices combined with innovative delivery systems [230].
The researchers’ interest is to discover various solutions for the transdermal administration of BV primarily safely, but also with satisfactory therapeutic effect, which has led to the use of the product embedded in nanoparticles as a delivery vehicle [16].

6.2. CV—Safety Profile

In 1986, LD 50 was determined for snake venom for the first time, using mouse models. Research has shown that venom obtained from the same species of the snake here but from different geographical areas may have different LD 50 values, and the approximate LD 50 for the snake Naja naja was determined in mice to be equal to 0.05 μg/g body weight [231]. A study conducted many years ago in vitro and in vivo by Angeletti concluded that NGF in Naja naja showed no toxic effects [232].
Other more recent research suggests that the clinical use of Naja atra venom (NAV) and cobrotoxin (the neurotoxin in NAV) would be safe. Thus, experiments on mice, using Bliss tests, established that the LD 50 of NAV venom was 102.3 mg/kg for oral administration, 996.6 μg/kg for intraperitoneal injection, and 623.9 μg/kg for intravenous injection. The researchers also measured the LD 50 for cobrotoxin and concluded that by subcutaneous injections it was 59.991 μg/kg, and by oral administration, it was about 90 μg/kg [107].

6.3. Ficus carica—Safety Profile

Ficus carica, in general, has a favorable safety profile, being used in various conditions without showing significant toxicity at controlled doses. In vitro and in vivo studies have shown that Ficus carica leaf extracts did not exhibit cell toxicity or hepatotoxic and nephrotoxic effects at certain doses [151,233,234,235,236].
In one study, to assess the irritating potential of a cream with Ficus carica fruit extract, patch tests were performed on both forearms of each volunteer on the first day of skin evaluation. An area of 5x4 cm was marked on each forearm, where 1.0 g of base was applied on the left forearm and the formulated cream on the right one, covered with surgical dressing. After 48 h, the patches were removed, and an experienced dermatologist examined the skin and found that there were no signs of irritation [150].
However, certain compounds such as furocoumarins and triterpenoids, can cause irritation and phototoxic reactions to topical application, which underscores the need for caution and further research to ensure safe use [237].

7. Modern Approaches to Delivering Bioactive Compounds to the Skin

Recent discoveries on controlled drug delivery systems and nanotechnology-based delivery methods can improve the targeted delivery of an exact amount of ingredient to the desired location, increase bioavailability, and reduce side effects occurring by routine administration [238].
The easy penetration through the skin of various natural or non-natural products has been studied since ancient times; modern approaches consist of encapsulation in nanocarriers (nanoparticles, ethosomes, liposomes, aquasomes, niosomes, transfersomes, novasomes, cubosomes, ultrasomes, photosomes, polymerosomes, fullerenes, dendrimers), the use of stimulus-sensitive materials (wearable devices, patches, etc.), physical methods (thermal ablation, laser microporation, iontophoresis, sonophoresis, electroporation, thermophoresis, or microneedle patches), and the inclusion of chemical permeation enhancers (peptides, alcohols, glycols, fatty alcohols, fatty acids, surfactants) [239,240,241,242,243,244].
In the case of cosmetics, the introduction of nanotechnology was a very important step in improving the overall health of the skin (including pigmentation, dehydration, wrinkles, and fine lines) by improving the distribution of the active ingredient, thus achieving superior and long-lasting efficacy [245,246]. By using nanotechnology, personalized cosmetic products can be made, and the shelf life of the product can be extended [247].
Microneedles (MN) are currently very successful in the cosmetic field, the primary purpose being to deliver various molecules into the skin without causing injury or insignificant damage [248]. Recently, Lim and collaborators used DLP 3D printing technology to create a delivery system for acetyl hexapeptide 3, a small peptide known for its safety and effectiveness as an anti-aging molecule. The results showed a good skin penetration capacity of the developed MN patch and a future potential in the delivery of anti-wrinkle products [249].
Hyaluronic acid-based microneedles with a content of bioactive peptides were designed by Avcil and collaborators and applied to 20 volunteers. A 25.8% reduction in wrinkles was observed, and an improvement in skin hydration by 15.4%, without the occurrence of side effects [250].
Studying and developing suitable formulations for the topical treatment of acne through the use of nanotechnology is a strategy capable of overcoming some of the disadvantages that can occur using natural products [251]. In the treatment of acne, the target site of action is the hair follicle, thus, nanomaterial systems are made for the delivery of the trans-follicular and follicular drugs [252]. It has been concluded that silver and gold nanoparticles have the potential to be used in the treatment of acne, but further controlled studies are needed to demonstrate clinical efficacy [253].
Lipid-based nanosystems that include liposomes, transfersomes, niosomes, invazomes, ethosomes, cubosomes, sphingosomes, acvazomes, and ufasomes, have been studied and have shown promising results for the transport of various anti-acne agents [254].

7.1. BV—Nanoformulations and Delivery Systems for Topical Use

Bee-sting therapy is recognized as a traditional therapeutic approach, but it has a few drawbacks, including considerable discomfort for patients. Due to the short half-life of melittin, repeated injections are required to maintain effective concentrations. It can induce inflammation and make it difficult to maintain constant blood concentrations [255].
Discoveries in drug delivery have introduced more complex approaches to BV therapy, including the use of controlled-release systems.

7.1.1. Niosomes

A recent study investigated the potential of melittin-laden liposomal vesicles against Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), and clinical isolates of the intermediate vancomycin Staphylococcus aureus (VISA). The liposomal vesicles were prepared for dermal and transdermal use, and surfactants (Tween 80 and Span 60) were used in different ratios. The effective inhibitory activity of melittin on skin pathogens has been demonstrated. Of the strains tested, VISA was more susceptible to melittin. This formulation also showed an excellent ability to improve drug distribution in the stratum corneum and was able to restrict the spread of bacterial infection in ex vivo pig-ear skin models. This observation suggests that melittin-laden niosomal vesicles have the potential to be further developed for skin treatment and may be candidates for topical application [256].

7.1.2. Nanoemulsions

To facilitate the passage of BV through the skin when used topically, a group of researchers used a nanoemulsion as a nanocarrier. The results of the study showed that the topical administration of water-in-oil nanoemulsion with a content of 18.75 or 9.37 μg/mL BV was able to significantly reduce inflammation in the paws of rat models with induced arthritis, compared to control groups, thus demonstrating the antirheumatic efficacy of the product [257].

7.1.3. Microneedles

With the help of polymeric microneedles made with hyaluronic acid, it has been demonstrated that the transdermal delivery of melittin could become a potential therapy with good results and high compliance in the treatment of rheumatoid arthritis. After modifying hyaluronic acid with methacrylate groups, microneedles with sustained-release properties were obtained [258].

7.2. Ficus carica—Nanoformulations and Delivery Systems for Topical Use

The researchers analyzed a combination of plant extracts, called 4HGF, which includes species such as Phellinus linteus grown on sprouted rice, Cordyceps militaris grown on sprouted soybeans, Polygonum multiflorum, Ficus carica, and coconut oil. The impact on hair growth of 4HGF encapsulated in nanoparticles composed of PGA and chitosan (PGA-4HGF) has been evaluated in both in vitro and in vivo experiments [259].
Previous studies have suggested that Polygonum multiflorum promotes hair regeneration, and coconut oil benefits skin and hair health [260,261,262,263]. Additionally, Phellinus linteus, Cordyceps militaris, and Ficus carica have been found to have anti-inflammatory properties, making them useful in stimulating hair growth [264,265,266,267].
PGA-4HGF nanoparticles can reach hair follicles in the basal layer of the skin, crossing the barrier of the stratum corneum, due to their size of about 400 nm, and improve blood circulation [268,269]. PGA-4HGF has been found to stimulate the β-catenin pathway, facilitating the transition from G1 to S phase by modulating cyclinD1 and CDK4 proteins, as well as increasing keratin II and melanin levels, thus contributing to sustainable hair growth. These results suggest that PGA nanocapsules for 4HGF delivery could represent a promising therapeutic solution for the treatment of hair growth problems [259].
Studies have been conducted with extracts of Ficus carica, embedded in an amphiphilic polymer matrix or gold and silver nanoparticles, their results offering promising prospects for wound treatment and tissue regeneration in diabetes [270,271].
Recent research has demonstrated that an advanced and effective approach to treating diabetes lesions is to use dressings containing polymers, nanoparticles, and various plant compounds [272,273].
Dressings containing Ficus carica extracts (FFE) have been reported to be effective in the treatment of diabetic wounds. A biomaterial composed of PXAG-PHB and FFE demonstrated complete wound healing within 72 h, without adverse reactions, and had strong antimicrobial activity (on Escherichia coli and Staphylococcus aureus). This compound stimulates cell proliferation, and the formation of new blood vessels, and has antioxidant and anti-inflammatory properties, making it a promising treatment for tissue regeneration in diabetic wounds [274].
Ultraviolet (UV) radiation generates reactive oxygen species (ROS) that affect DNA and collagen. Once on the surface of the skin, it contributes to the synthesis of vitamin D3, but can also cause immunosuppression, photoaging, and skin cancer [275,276,277].
Synthetic sunscreens are effective, but photostability and toxicity issues limit their use. In contrast, plants have developed, through evolution, natural mechanisms of protection against UV radiation. Natural antioxidants and sunblockers have proven to be increasingly valuable for cosmetic formulations [278]. The results of a study highlighted the significant effect of silver nanoparticles (AgNPs) stabilized with Ficus carica extract on the sun protection factor (SPF) of various natural extracts and commercial sunscreen products. The AgNPs, obtained by adding latex to the silver nitrate solution, were characterized as spherical, with an average size of 163.7 nm and a cubic structure of the fcc type, with a stability of six months. The incorporation of AgNPs at concentrations of 2% and 4% in sunscreens demonstrated a significant increase in the sun protection factor, with improvements ranging from 0.1% to 12.175% compared to the standard control. This synergistic effect suggests that silver nanoparticles synthesized using Ficus carica latex may enhance the efficacy of commercial sunscreens, providing improved sun protection [279].

8. Possible Synergies Between BV, CV and Ficus carica

Although this review is based on existing literature data, we also want to consider the synergistic potential of the natural products studied when used together in cosmetic formulations. The hypothesis of a synergy is based on the complementarity of the bioactive effects of each ingredient, which could provide significant cumulative benefits for skin health and beauty, maximizing regeneration, preventing ageing and protecting against oxidative stress (Table 4).

9. Conclusions

In scientific literature, BV is recognized for its remarkable therapeutic potential, especially in the treatment of inflammatory, autoimmune, and oncological conditions. However, research is still at an early stage, and rigorous research through well-designed clinical trials, standardized protocols and strict safety assessments is needed to turn these findings into effective clinical treatments. As far as dermatology is concerned, BV has shown great benefits, especially for skin tissue regeneration and anti-aging therapies. Due to its antibacterial and anti-inflammatory properties, it is also used in the treatment of some skin conditions, such as acne. However, concerns about possible allergic reactions need to be seriously addressed, especially in the case of cosmetics. BV holds considerable potential in the pharmaceutical and cosmetic fields. And in this context, substantial efforts are being made to develop safe methods of administration, integrated with modern technologies aimed at minimizing the incidence of adverse effects and expanding clinical and therapeutic applicability.
In recent decades, only a small fraction of the components of CV have been identified, characterized, and approved for use in pharmaceuticals, while numerous other components are still in the preclinical or clinical trial phase for possible therapeutic application. It has recently been highlighted that cobra venom, due to its main components (neurotoxins, cardiotoxins, cobra venom factor, phospholipase A2, and nerve growth factor) has multiple therapeutic actions, demonstrating significant potential for the development of drugs intended to treat various conditions. The anticancer activities of CV represent one of the most promising therapeutic characteristics and have been intensively researched and reviewed in recent years. A recent discovery of scientific interest is the ability of CV to intervene in the prevention and treatment of COVID-19. Although it has a huge therapeutic value, CV is not yet fully exploited, and further studies are needed to investigate the mechanisms underlying different pharmacological actions and especially to study the safety profile.
In the current context of scientific research, Ficus carica continues to be a topic of interest due to its bioactive potential and its extensive applicability in various fields, including cosmetics and therapeutics. Preliminary studies have demonstrated a wide range of beneficial properties of compounds isolated from this species, but the need for further research is evident to optimize its use in clinical and commercial practices. In the cosmetic industry, Ficus carica is of considerable interest due to its antioxidant, anti-inflammatory, and photoprotective activities. Identifying and characterizing in more detail the compounds responsible for these effects, such as polyphenols and flavonoids, could lead to the development of new dermo-cosmetic products aimed at preventing premature skin aging, protecting against UV radiation and relieving various skin conditions, including acne and atopic dermatitis. In addition, exploring the synergy between Ficus carica extracts and other natural or synthetic substances can open new horizons in the formulation of products with increased efficacy and optimal tolerability. In addition to cosmetic applications, the possible therapeutic role of Ficus carica in the management of other conditions requires further investigation. Future research should focus on elucidating the molecular mechanisms by which Ficus carica extracts exert their biological effects, as well as conducting rigorous clinical trials to validate their efficacy and safety. These efforts will help strengthen the position of the fig tree as a valuable ingredient both in traditional medicine and in the development of innovative therapeutic and cosmetic solutions.
The use of nanoparticles has proven effective in delivering various bioactive compounds from BV and Ficus carica to the skin, thus improving stability, and bioavailability and allowing for targeted delivery.
Although the three products have different origins and chemical compositions, these natural sources of bioactive compounds share several common pharmacological elements (anti-inflammatory, antioxidant, immunomodulatory, healing, antimicrobial, and neuroprotective), which make them promising candidates for various applications in the cosmetic and pharmaceutical industries.
Ficus carica can amplify the effectiveness of BV and CV, helping to enhance their beneficial effects and reducing the risk of adverse effects due to its well-tolerated nature.
It would be interesting for future research directions to focus on exploring synergies between these ingredients and developing products that make the most of their combined potential. Rigorous clinical trials and research into the molecular mechanisms by which these substances interact will be essential to develop innovative solutions that not only treat the visible signs of aging but also improve skin health in the long term. By investigating these synergies and optimizing formulations, new perspectives will open in the pharmaceutical and cosmetics industry, offering more efficient and safer products.
Given the exciting challenges in the field of discovering natural ingredients for various uses, we are motivated to continue scientific explorations and end this journey with the confidence that new bioactive compounds are waiting to be discovered, ready to contribute to the advancement of medicine and skin care, and transforming natural resources into valuable allies for human health.

Author Contributions

All authors contributed equally to this work as follows: conceptualization, M.D. and O.D.B.; methodology, M.D., O.D.B. and C.G.; software, A.M.C. and M.D.; validation, A.L.T., A.M.C. and C.S.S.; formal analysis, O.D.B., A.L.T., C.G. and A.M.C.; investigation, C.G., O.D.B. and L.C.N.; resources, A.L.T., M.D., C.G. and C.S.S.; data curation, L.C.N., A.M.C. and M.D.; writing—preparation of the original draft, C.G., O.D.B. and A.M.C.; writing—revision and editing L.C.N. and M.D.; review, A.L.T., L.C.N., A.M.C. and C.S.S.; surveillance, A.L.T., C.S.S. and L.C.N.; project administration, A.L.T., C.S.S. and C.G.; funding acquisition, C.S.S. and A.L.T. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. The present study was academically supported by the “Dunarea de Jos” University in Galati, Romania, through the MIC-DIR Integrated Multidisciplinary Center for Dermatological Interface Research (CIM-CID), and all the persons included in this section have consented to the acknowledgment. The APC was paid by “Dunarea de Jos” University, 800010 Galati, Romania, Strada Domneasca 47, Galati, 800008 Romania. VAT-RO27232142.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Majtan, J.; Bucekova, M.; Jesenak, M. Natural Products and Skin Diseases. Molecules 2021, 26, 4489. [Google Scholar] [CrossRef] [PubMed]
  2. Zhang, Y. Why do we study animal toxins? Zool. Res. 2015, 36, 183–222. [Google Scholar] [CrossRef]
  3. Beraud, E.; Chandy, K.G. Therapeutic potential of peptide toxins that target ion channels. Inflamm. Allergy Drug Targets. 2011, 10, 322–342. [Google Scholar] [CrossRef]
  4. Mohamed Abd El-Aziz, T.; Garcia Soares, A.; Stockand, J.D. Snake Venoms in Drug Discovery: Valuable Therapeutic Tools for Life Saving. Toxins 2019, 11, 564. [Google Scholar] [CrossRef] [PubMed]
  5. Michalak, M. Plant-Derived Antioxidants: Significance in Skin Health and the Ageing Process. Int. J. Mol. Sci. 2022, 23, 585. [Google Scholar] [CrossRef]
  6. Menaa, F. Skin anti-aging benefits of phytoterapeutics-based emulsions. Pharm. Anal. Acta 2014, 5, 168. [Google Scholar] [CrossRef]
  7. Buzia, O.D.; Fasie, V.; Mardare, N.; Diaconu, C.; Gurau, G.; Tatu, A.L. Formulation, Preparation, Physico-chimical Analysis, Microbiological Peculiarities and Therapeutic Challenges of Extractive Solution of Kombucha. Rev. Chim. 2018, 69, 720–724. [Google Scholar] [CrossRef]
  8. Anghel, L.; Baroiu, L.; Popazu, C.R.; Pătraș, D.; Fotea, S.; Nechifor, A.; Ciubara, A.; Nechita, L.; Mușat, C.L.; Stefanopol, I.A.; et al. Benefits and adverse events of melatonin use in the elderly (Review). Exp. Ther. Med. 2022, 23, 219. [Google Scholar] [CrossRef]
  9. Jadoon, S.; Karim, S.; Bin Asad, M.H.; Akram, M.R.; Khan, A.K.; Malik, A.; Chen, C.; Murtaza, G. Anti-Aging Potential of Phytoextract Loaded-Pharmaceutical Creams for Human Skin Cell Longetivity. Oxidative Med. Cell. Longev. 2015, 2015, 709628. [Google Scholar] [CrossRef]
  10. Kowalczyk, S.; Grymel, M.; Bilik, J.; Kula, W.; Wawoczny, A.; Grymel, P.; Gillner, D. Selected Plants as Sources of Natural and Active Ingredients for Cosmetics of the Future. Appl. Sci. 2024, 14, 3487. [Google Scholar] [CrossRef]
  11. Ali AM, H. Advancements in bee venom bioactivities for current therapeutic applications: A Review. Adv. Life Sci. 2024, 11, 49–55. [Google Scholar]
  12. Zhang, S.; Liu, Y.; Ye, Y.; Wang, X.-R.; Lin, L.-T.; Xiao, L.-Y.; Zhou, P.; Shi, G.-X.; Liu, C.-Z. Bee venom therapy: Potential mechanisms and therapeutic applications. Toxicon 2018, 148, 64–73. [Google Scholar] [CrossRef] [PubMed]
  13. Bellik, Y. Bee Venom: Its potential use in alternative medicine. Anti-Infect. Agents 2015, 13, 3–16. [Google Scholar] [CrossRef]
  14. Abdela, N.; Jilo, K. Bee venom and its therapeutic values: A review. Adv. Life Sci. Technol. 2016, 44, 18–22. [Google Scholar]
  15. Bava, R.; Castagna, F.; Musella, V.; Lupia, C.; Palma, E.; Britti, D. Therapeutic Use of Bee Venom and Potential Applications in Veterinary Medicine. Vet. Sci. 2023, 10, 119. [Google Scholar] [CrossRef]
  16. Khalil, A.; Elesawy, B.H.; Ali, T.M.; Ahmed, O.M. Bee Venom: From Venom to Drug. Molecules 2021, 26, 4941. [Google Scholar] [CrossRef]
  17. Essam Elenany, Y. Factors affecting the quantity and quality of honey bee venom collected from entrance and inside the beehive under Egyptian conditions. J. Apic. Res. 2024, 1–7. [Google Scholar] [CrossRef]
  18. Otręba, M.; Marek, Ł.; Tyczyńska, N.; Stojko, J.; Rzepecka-Stojko, A. Bee venom, honey, and royal jelly in the treatment of bacterial infections of the oral cavity: A review. Life. 2021, 11, 1311. [Google Scholar] [CrossRef]
  19. Pucca, M.B.; Cerni, F.A.; Oliveira, I.S.; Jenkins, T.P.; Argemí, L.; Sørensen, C.V.; Ahmadi, S.; Barbosa, J.E.; Laustsen, A.H. Bee updated: Current knowledge on bee venom and bee envenoming therapy. Front. Immunol. 2019, 10, 2090. [Google Scholar] [CrossRef]
  20. Sharaf, M.; Zahra, A.A.; Alharbi, M.; Mekky, A.E.; Shehata, A.M.; Alkhudhayri, A.; Ali, A.M.; Al Suhaimi, E.A.; Zakai, S.A.; Al Harthi, N.; et al. Bee chitosan nanoparticles loaded with apitoxin as a novel approach to eradication of common human bacterial, fungal pathogens and treating cancer. Front. Microbiol. 2024, 15, 1345478. [Google Scholar] [CrossRef]
  21. Farook, U.B.; Dar, S.A.; Arifie, U.; Javid, R.; Khaliq, N.; Singh, R.; Pandit, B.A. Bee venom: Composition and therapeutic potential. In Honey Bees, Beekeeping and Bee Products; CRC Press: Boca Raton, FL, USA, 2024; pp. 189–202. ISBN 9781003354116. [Google Scholar]
  22. Son, D.J.; Lee, J.W.; Lee, Y.H.; Song, H.S.; Lee, C.K.; Hong, J.T. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol. Ther. 2007, 115, 246–270. [Google Scholar] [CrossRef] [PubMed]
  23. Lee, G.; Bae, H. Anti-inflammatory applications of melittin, a major component of bee venom: Detailed mechanism of action and adverse effects. Molecules 2016, 21, 616. [Google Scholar] [CrossRef] [PubMed]
  24. Gong, H.; Hu, X.; Zhang, L.; Fa, K.; Liao, M.; Liu, H.; Fragneto, G.; Campana, M.; Lu, J.R. How do antimicrobial peptides disrupt the lipopolysaccharide membrane leaflet of Gram-negative bacteria? J. Colloid Interface Sci. 2023, 637, 182–192. [Google Scholar] [CrossRef]
  25. Memariani, H.; Memariani, M.; Moravvej, H.; Shahidi-Dadras, M. Melittin: A venom-derived peptide with promising anti-viral properties. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 5–17. [Google Scholar] [CrossRef]
  26. Kurek-Górecka, A.; Górecki, M.; Rzepecka-Stojko, A.; Balwierz, R.; Stojko, J. Bee Products in Dermatology and Skin Care. Molecules 2020, 25, 556. [Google Scholar] [CrossRef] [PubMed]
  27. Zhang, S.; Chen, Z. Melittin exerts an antitumor effect on non-small cell lung cancer cells. Mol. Med. Rep. 2017, 16, 3581–3586. [Google Scholar] [CrossRef]
  28. Nguyen, C.D.; Lee, G. Neuroprotective Activity of Melittin-The Main Component of Bee Venom-Against Oxidative Stress Induced by Aβ25-35 in In Vitro and In Vivo Models. Antioxidants 2021, 10, 1654. [Google Scholar] [CrossRef]
  29. Wehbe, R.; Frangieh, J.; Rima, M.; El Obeid, D.; Sabatier, J.M.; Fajloun, Z. Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules 2019, 24, 2997. [Google Scholar] [CrossRef]
  30. Elieh Ali Komi, D.; Shafaghat, F.; Zwiener, R.D. Immunology of bee venom. Clin. Rev. Allergy Immunol. 2018, 54, 386–396. [Google Scholar] [CrossRef] [PubMed]
  31. Dudler, T.; Chen, W.-Q.; Wang, S.; Schneider, T.; Annand, R.R.; Dempcy, R.O.; Crameri, R.; Gmachl, M.; Suter, M.; Gelb, M.H. High-level expression in Escherichia coli and rapid purification of enzymatically active honey bee venom phospholipase A2. Biochim. Biophys. Acta (BBA)-Lipids Lipid Metab. 1992, 1165, 201–210. [Google Scholar] [CrossRef]
  32. Oršolić, N. Bee venom in cancer therapy. Cancer Metastasis Rev. 2012, 31, 173–194. [Google Scholar] [CrossRef] [PubMed]
  33. Hossen, M.; Gan, S.H.; Khalil, M. Melittin, a potential natural toxin of crude bee venom: Probable future arsenal in the treatment of diabetes mellitus. J. Chem. 2017, 2017, 4035626. [Google Scholar] [CrossRef]
  34. Bala, E.; Hazarika, R.; Singh, P.; Yasir, M.; Shrivastava, R. A biological overview of Hyaluronidase: A venom enzyme and its inhibition with plants materials. Mater. Today Proc. 2018, 5, 6406–6412. [Google Scholar] [CrossRef]
  35. Cherniack, E.P.; Govorushko, S. To bee or not to bee: The potential efficacy and safety of bee venom acupuncture in humans. Toxicon 2018, 154, 74–78. [Google Scholar] [CrossRef] [PubMed]
  36. Hanson, J.M.; Morley, J.; Soria-Herrera, C. Anti-inflammatory property of 401 (MCD-peptide), a peptide from the venom of the bee Apis mellifera (L.). Br. J. Pharmacol. 1974, 50, 383. [Google Scholar] [CrossRef]
  37. Vetter, R.S.; Visscher, P.K. Bites and stings of medically important venomous arthropods. Int. J. Dermatol. 1998, 37, 481–496. [Google Scholar] [CrossRef]
  38. Moreno, M.; Giralt, E. Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: Melittin, apamin and mastoparan. Toxins 2015, 7, 1126–1150. [Google Scholar] [CrossRef]
  39. Lee, J.-D.; Park, H.-J.; Chae, Y.; Lim, S. An overview of bee venom acupuncture in the treatment of arthritis. Evid. -Based Complement. Altern. Med. 2005, 2, 79–84. [Google Scholar] [CrossRef]
  40. Niculet, E.; Chioncel, V.; Elisei, A.M.; Miulescu, M.; Buzia, O.D.; Nwabudike, L.C.; Craescu, M.; Draganescu, M.; Bujoreanu, F.; Marinescu, E.; et al. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review). Exp. Ther. Med. 2021, 21, 263. [Google Scholar] [CrossRef]
  41. Jeong, C.H.; Cheng, W.N.; Bae, H.; Lee, K.W.; Han, S.M.; Petriello, M.C.; Lee, H.G.; Seo, H.G.; Han, S.G. Bee venom decreases LPS-induced inflammatory responses in bovine mammary epithelial cells. J. Microbiol. Biotechnol. 2017, 27, 1827–1836. [Google Scholar] [CrossRef]
  42. Baek, Y.H.; Huh, J.E.; Lee, J.D.; Choi, D.Y.; Park, D.S. Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: Mediation by α2-Adrenoceptors. Brain Res. 2006, 1073–1074, 305–310. [Google Scholar] [CrossRef] [PubMed]
  43. You, C.E.; Moon, S.H.; Lee, K.H.; Kim, K.H.; Park, C.W.; Seo, S.J.; Cho, S.H. Effects of emollient containing bee venom on atopic dermatitis: A double-blinded, randomized, base-controlled, multicenter study of 136 patients. Ann. Dermatol. 2016, 28, 593–599. [Google Scholar] [CrossRef] [PubMed]
  44. Askari, P.; Namaei, M.H.; Ghazvini, K.; Hosseini, M. In vitro and in vivo toxicity and antibacterial efficacy of melittin against clinical extensively drug-resistant bacteria. BMC Pharmacol. Toxicol. 2021, 22, 42. [Google Scholar] [CrossRef]
  45. El-Seedi, H.; El-Wahed, A.A.; Yosri, N.; Musharraf, S.G.; Chen, L.; Moustafa, M.; Zou, X.; Al-Mousawi, S.; Guo, Z.; Khatib, A.; et al. Antimicrobial properties of Apis mellifera’s bee venom. Toxins 2020, 12, 451. [Google Scholar] [CrossRef]
  46. Choi, J.H.; Jang, A.Y.; Lin, S.; Lim, S.; Kim, N.; Park, K.; Han, S.-M.; Yeo, J.-H.; Seo, H.S. Melittin, a honeybee venom-derived antimicrobial peptide, may target methicillin-resistant Staphylococcus aureus. Mol. Med. Rep. 2015, 12, 6483–6490. [Google Scholar] [CrossRef] [PubMed]
  47. AL-Ani, I.; Zimmermann, S.; Reichling, J.; Wink, M. Pharmacological synergism of bee venom and melittin with antibiotics and plant secondary metabolites against multi-drug resistant microbial pathogens. Phytomedicine 2015, 22, 245–255. [Google Scholar] [CrossRef]
  48. Han, S.; Yeo, J.; Baek, H.; Lin, S.M.; Meyer, S.; Molan, P. Postantibiotic effect of purified melittin from honeybee (Apis mellifera) venom against Escherichia coli and Staphylococcus aureus. J. Asian Nat. Prod. Res. 2009, 11, 796–804. [Google Scholar] [CrossRef]
  49. Lubke, L.L.; Garon, C.F. The antimicrobial agent melittin exhibits powerful in vitro inhibitory effects on the lyme disease spirochete. Clin. Infect. Dis. 1997, 25, S48–S51. [Google Scholar] [CrossRef]
  50. Socarras, K.; Theophilus, P.A.S.; Torres, J.P.; Gupta, K.; Sapi, E. Antimicrobial Activity of Bee Venom and Melittin against Borrelia burgdorferi. Antibiotics 2017, 6, 31. [Google Scholar] [CrossRef]
  51. Uddin, M.B.; Lee, B.-H.; Nikapitiya, C.; Kim, J.-H.; Kim, T.-H.; Lee, H.-C.; Kim, C.G.; Lee, J.-S.; Kim, C.-J. Inhibitory effects of bee venom and its components against viruses in vitro and in vivo. J. Microbiol. 2016, 54, 853–866. [Google Scholar] [CrossRef]
  52. Sarhan, M.; El-Bitar AM, H.; Hotta, H. Potent virucidal activity of honeybee “Apis mellifera” venom against Hepatitis C Virus. Toxicon 2020, 188, 55–64. [Google Scholar] [CrossRef] [PubMed]
  53. Uzair, B.; Bushra, R.; Khan, B.A.; Zareen, S.; Fasim, F. Potential uses of venom proteins in treatment of HIV. Protein Pept. Lett. 2018, 25, 619–625. [Google Scholar] [CrossRef] [PubMed]
  54. Prakash, S.; Bhargava, H. Apis cerana bee venom: It’s antidiabetic and anti-dandru activity against malassezia furfur. World Appl. Sci. J. 2014, 32, 343–348. [Google Scholar]
  55. Park, C.; Lee, D.G. Melittin induces apoptotic features in candida albicans. Biochem. Biophys. Res. Commun. 2010, 394, 170–172. [Google Scholar] [CrossRef] [PubMed]
  56. Nainu, F.; Masyita, A.; Bahar, M.A.; Raihan, M.; Prova, S.R.; Mitra, S.; Emran, T.B.; Simal-Gandara, J. Pharmaceutical Prospects of Bee Products: Special Focus on Anticancer, Antibacterial, Antiviral, and Antiparasitic Properties. Antibiotics 2021, 10, 822. [Google Scholar] [CrossRef]
  57. Tatu, A.L.; Cristea, V.C. Pityriasis Folliculorum of the Back Thoracic Area: Pityrosporum, Keratin Plugs, or Demodex Involved? J. Cutan. Med. Surg. 2017, 21, 441. [Google Scholar] [CrossRef]
  58. Shin, S.; Ye, M.; Choi, S.; Park, K. The effects of melittin and apamin on airborne Fungi-Induced chemical mediator and extracellular matrix production from nasal polyp fibroblasts. Toxicon 2017, 9, 384. [Google Scholar] [CrossRef] [PubMed]
  59. Ye, M.; Chung, H.S.; Lee, C.; Yoon, M.S.; Yu, A.R.; Kim, J.S.; Hwang, D.S.; Shim, I.; Bae, H. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease. J. Neuroinflammation 2016, 13, 10. [Google Scholar] [CrossRef]
  60. Alvarez-Fischer, D.; Noelker, C.; Vulinović, F.; Grünewald, A.; Chevarin, C.; Klein, C.; Oertel, W.H.; Hirsch, E.C.; Michel, P.P.; Hartmann, A. Bee Venom and Its Component Apamin as Neuroprotective Agents in a Parkinson Disease Mouse Model. PLoS ONE 2013, 8, e61700. [Google Scholar] [CrossRef]
  61. Cho, S.-Y.; Shim, S.-R.; Rhee, H.Y.; Park, H.-J.; Jung, W.-S.; Moon, S.-K.; Park, J.-M.; Ko, C.-N.; Cho, K.-H.; Park, S.U. Effectiveness of acupuncture and bee venom acupuncture in idiopathic parkinson’s disease. Park. Report. Disorder. 2012, 18, 948–952. [Google Scholar] [CrossRef]
  62. Martinello, M.; Mutinelli, F. Antioxidant activity in bee products: A review. Antioxidants 2021, 10, 71. [Google Scholar] [CrossRef] [PubMed]
  63. Shaaban, A.M.M.; Hamza, R.G.; El Shahat, A.N. Studying the ameliorative effect of bee venom against damage and inflammation induced in gamma-irradiated rats. Arab. J. Nucl. Sci. Appl. 2019, 52, 178–184. [Google Scholar] [CrossRef]
  64. Kim, B.-Y.; Lee, K.-S.; Jin, B.-R. Antioxidant Activity and Mechanism of Action of Amwaprin: A Protein in Honeybee (Apis mellifera) Venom. Antioxidants 2024, 13, 469. [Google Scholar] [CrossRef]
  65. Alunno, A.; Manetti, M.; Caterbi, S.; Ibba-Manneschi, L.; Bistoni, O.; Bartoloni, E.; Valentini, V.; Terenzi, R.; Gerli, R. Altered immunoregulation in rheumatoid arthritis: The role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediat. Inflamm. 2015, 2015, 751793. [Google Scholar] [CrossRef] [PubMed]
  66. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. [Google Scholar] [CrossRef] [PubMed]
  67. Al Naggar, Y.; Giesy, J.P.; Abdel-Daim, M.M.; Ansari, M.J.; Al-Kahtani, S.N.; Yahya, G. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic? Saudi J. Biol. Sci. 2021, 28, 1519–1527. [Google Scholar] [CrossRef] [PubMed]
  68. Lima, W.G.; Brito JC, M.; Nizer WS, D. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2). Phytother. Res. 2021, 35, 743–750. [Google Scholar] [CrossRef]
  69. Moscu, C.A.; Marina, V.; Anghele, M.; Anghele, A.D.; Dragomir, L. Did Personality Type Influence Burn Out Syndrome Manifestations During COVID-19 Pandemic? Int. J. Gen. Med. 2022, 15, 5487–5498. [Google Scholar] [CrossRef]
  70. Yacoub, T.; Rima, M.; Karam, M.; Fajloun, J.S.A.Z. Antimicrobials from Venomous Animals: An Overview. Molecules 2020, 25, 2402. [Google Scholar] [CrossRef] [PubMed]
  71. Uetz, P.; Koo, M.S.; Aguilar, R.; Brings, E.; Catenazzi, A.; Chang, A.T.; Wake, D.B. A Quarter Century of Reptile and Amphibian Databases. Herpetol. Rev. 2021, 52, 246–255. [Google Scholar]
  72. Ratanabanangkoon, K. A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms. Front. Immunol. 2021, 12, 668328. [Google Scholar] [CrossRef] [PubMed]
  73. Koh, D.C.; Armugam, A.; Jeyaseelan, K. Snake venom components and their applications in biomedicine. Cell Mol. Life Sci. 2006, 63, 3030–3041. [Google Scholar] [CrossRef] [PubMed]
  74. Allaoui, H.; Rached, N.; Marrakchi, N.; Cherif, A.; Mosbah, A.; Messadi, E. In Silico Study of the Mechanisms Underlying the Action of the Snake Natriuretic-Like Peptide Lebetin 2 during Cardiac Ischemia. Toxins 2022, 14, 787. [Google Scholar] [CrossRef]
  75. Waheed, H.; Moin, S.F.; Choudhary, M.I. Snake Venom: From Deadly Toxins to Life-saving Therapeutics. Curr. Med. Chem. 2017, 24, 1874–1891. [Google Scholar] [CrossRef]
  76. Stepensky, D. Pharmacokinetics of Toxin-Derived Peptide Drugs. Toxins 2018, 10, 483. [Google Scholar] [CrossRef]
  77. Ho, S.J.; Brighton, T.A. Ximelagatran: Direct thrombin inhibitor. Vasc. Health Risk Manag. 2006, 2, 49–58. [Google Scholar] [CrossRef]
  78. Augusto-de-Oliveira, C.; Stuginski, D.R.; Kitano, E.S.; Andrade-Silva, D.; Liberato, T.; Fukushima, I.; Serrano, S.M.; Zelanis, A. Dynamic Rearrangement in Snake Venom Gland Proteome: Insights into Bothrops jararaca Intraspecific Venom Variation. J. Proteome Res. 2016, 15, 3752–3762. [Google Scholar] [CrossRef] [PubMed]
  79. Munawar, A.; Ali, S.A.; Akrem, A.; Betzel, C. Snake Venom Peptides: Tools of Biodiscovery. Toxins 2018, 10, 474. [Google Scholar] [CrossRef]
  80. Li, S.; Wang, J.; Zhang, X.; Ren, Y.; Wang, N.; Zhao, K.; Chen, X.; Zhao, C.; Li, X.; Shao, J.; et al. Proteomic characterization of two snake venoms: Naja naja atra and Agkistrodon halys. Biochem. J. 2004, 384, 119–127. [Google Scholar] [CrossRef]
  81. Hassan-Puttaswamy, V.; Adams, D.J.; Kini, R.M. A Distinct Functional Site in Omega-Neurotoxins: Novel Antagonists of Nicotinic Acetylcholine Receptors from Snake Venom. ACS Chem. Biol. 2015, 10, 2805–2815. [Google Scholar] [CrossRef]
  82. Liang, Y.X.; Zhang, Z.Y.; Zhang, R. Antinociceptive Effect of Najanalgesin from Naja Naja Atra in a Neuropathic Pain Model via Inhibition of c-Jun NH2-terminal Kinase. Chin. Med. J. 2015, 128, 2340–2345. [Google Scholar] [CrossRef] [PubMed]
  83. Xu, J.M.; Song, S.T.; Feng, F.Y.; Huang, F.L.; Yang, Y.; Xie, G.R.; Xu, L.G.; Zhang, C.Z.; Bruno, M.; Paradiso, A. Cobrotoxin-containing analgesic compound to treat chronic moderate to severe cancer pain: Results from a randomized, double-blind, cross-over study and from an open-label study. Oncol. Rep. 2006, 16, 1077–1084. [Google Scholar] [CrossRef]
  84. Zhu, Q.; Huang, J.; Wang, S.Z.; Qin, Z.H.; Lin, F. Cobrotoxin extracted from Naja atra venom relieves arthritis symptoms through anti-inflammation and immunosuppression effects in rat arthritis model. J. Ethnopharmacol. 2016, 194, 1087–1095. [Google Scholar] [CrossRef]
  85. Saha, A.; Gomes, A.; Chakravarty, A.; Biswas, A.; Giri, B.; Dasgupta, S. CNS and anticonvulsant activity of a non-protein toxin (KC-MMTx) isolated from King Cobra (Ophiophagus hannah) venom. Toxicon 2006, 47, 296–303. [Google Scholar] [CrossRef]
  86. Alrajhi, A.A.; Almohaizeie, A. Snake venom preparation for drug-resistant human immunodeficiency virus. Ann. Saudi Med. 2008, 28, 292–293. [Google Scholar] [CrossRef] [PubMed]
  87. Konshina, A.G.; Dubovskii, P.V.; Efremov, R.G. Structure and dynamics of cardiotoxins. Curr. Protein Pept. Sci. 2012, 13, 570–584. [Google Scholar] [CrossRef]
  88. Stevens-Truss, R.; Hinman, C.L. Activities of cobra venom cytotoxins toward heart and leukemic T-cells depend on localized amino acid differences. Toxicon 1997, 35, 659–669. [Google Scholar] [CrossRef] [PubMed]
  89. Kazandjian, T.D.; Arrahman, A.; Still, K.B.M.; Somsen, G.W.; Vonk, F.J.; Casewell, N.R.; Wilkinson, M.C.; Kool, J. Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib. Toxins 2021, 13, 302. [Google Scholar] [CrossRef]
  90. Abdullah, N.A.H.; Sainik, N.Q.A.V.; Esa, E.; Muhamad Hendri, N.A.; Ahmad Rusmili, M.R.; Hodgson, W.C.; Shaikh, M.F.; Othman, I. Neuroprotective effect of phospholipase A2 from Malaysian Naja sumatrana venom against H2O2-induced cell damage and apoptosis. Front. Pharmacol. 2022, 13, 935418. [Google Scholar] [CrossRef]
  91. Armugam, A.; Cher, C.D.; Lim, K.; Koh, D.C.; Howells, D.W.; Jeyaseelan, K. A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis. BMC Neurosci. 2009, 10, 120. [Google Scholar] [CrossRef]
  92. Sudarshan, S.; Dhananjaya, B.L. Antibacterial activity of an acidic phospholipase A2 (NN-XIb-PLA2) from the venom of Naja naja (Indian cobra). SpringerPlus 2016, 5, 112. [Google Scholar] [CrossRef] [PubMed]
  93. Vogel, C.W.; Fritzinger, D.C. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion. Toxicon 2010, 56, 1198–1222. [Google Scholar] [CrossRef] [PubMed]
  94. Kock, M.A.; Hew, B.E.; Bammert, H.; Fritzinger, D.C.; Vogel, C.W. Structure and function of recombinant cobra venom factor. J. Biol. Chem. 2004, 279, 30836–30843. [Google Scholar] [CrossRef] [PubMed]
  95. Sunagar, K.; Fry, B.G.; Jackson, T.N.; Casewell, N.R.; Undheim, E.A.; Vidal, N.; Ali, S.A.; King, G.F.; Vasudevan, K.; Vasconcelos, V.; et al. Molecular evolution of vertebrate neurotrophins: Co-option of the highly conserved nerve growth factor gene into the advanced snake venom arsenalf. PLoS ONE 2013, 8, e81827. [Google Scholar] [CrossRef]
  96. Tan, K.K.; Bay, B.H.; Gopalakrishnakone, P. L-amino acid oxidase from snake venom and its anticancer potential. Toxicon 2018, 144, 7–13. [Google Scholar] [CrossRef] [PubMed]
  97. Fung, S.Y.; Lee, M.L.; Tan, N.H. Molecular mechanism of cell death induced by king cobra (Ophiophagus hannah) venom l-amino acid oxidase. Toxicon 2015, 96, 38–45. [Google Scholar] [CrossRef]
  98. Gazerani, P.; Cairns, B.E. Venom-based biotoxins as potential analgesics. Expert Rev. Neurother. 2014, 14, 1261–1274. [Google Scholar] [CrossRef]
  99. Chen, Z.X.; Zhang, H.L.; Gu, Z.L.; Chen, B.W.; Han, R.; Reid, P.F.; Raymond, L.N.; Qin, Z.H. A long-form alpha-neurotoxin from cobra venom produces potent opioid-independent analgesia. Acta Pharmacol. Sin. 2006, 27, 402–408. [Google Scholar] [CrossRef]
  100. Jiang, W.J.; Liang, Y.X.; Han, L.P.; Qiu, P.X.; Yuan, J.; Zhao, S.J. Purification and characterization of a novel antinociceptive toxin from Cobra venom (Naja naja atra). Toxicon 2008, 52, 638–646. [Google Scholar] [CrossRef]
  101. Ruan, Y.; Yao, L.; Zhang, B.; Zhang, S.; Guo, J. Anti-inflammatory effects of Neurotoxin-Nna, a peptide separated from the venom of Naja naja atra. BMC Complement. Altern. Med. 2013, 13, 86. [Google Scholar] [CrossRef]
  102. Wang, S.Z.; He, H.; Han, R.; Zhu, J.L.; Kou, J.Q.; Ding, X.L.; Qin, Z.-H. The protective effects of cobra venom from Naja naja atra on acute and chronic nephropathy. Evidence-Based Complement. Altern. Med. 2013, 2013, 478049. [Google Scholar] [CrossRef]
  103. Zhu, K.Z.; Liu, Y.L.; Gu, J.H.; Qin, Z.H. Antinociceptive and anti-inflammatory effects of orally administrated denatured Naja naja atra venom on murine rheumatoid arthritis models. Evid.-Based Complement. Altern. Med. 2013, 2013, 616241. [Google Scholar] [CrossRef]
  104. Avalo, Z.; Barrera, M.C.; Agudelo-Delgado, M.; Tobón, G.J.; Cañas, C.A. Biological Effects of Animal Venoms on the Human Immune System. Toxins 2022, 14, 344. [Google Scholar] [CrossRef]
  105. Yourist, J.E.; Haines, H.G.; Miller, K.D. Inhibition of herpes simplex virus replication by cobra alpha-neurotoxoid. J. Gen. Virol. 1983, 64, 1475–1481. [Google Scholar] [CrossRef] [PubMed]
  106. Lee, M.L.; Tan, N.H.; Fung, S.Y.; Sekaran, S.D. Antibacterial action of a heat-stable form of L-amino acid oxidase isolated from king cobra (Ophiophagus hannah) venom. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2011, 153, 237–242. [Google Scholar] [CrossRef]
  107. Wang, S.-Z.; Qin, Z.-H. Anti-Inflammatory and Immune Regulatory Actions of Naja naja atra Venom. Toxins 2018, 10, 100. [Google Scholar] [CrossRef]
  108. Zhang, L.; Feng, X.; Zhang, D.; Jiang, C.; Mei, H.; Wang, J.; Xie, M. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: Prevalence, risk factors, and outcome. Circulation 2020, 142, 114–128. [Google Scholar] [CrossRef]
  109. Lin, F.; Reid, P.F.; Qin, Z.H. Cobrotoxin could be an effective therapeutic for COVID-19. Acta Pharmacol. Sin. 2020, 41, 1258–1260. [Google Scholar] [CrossRef] [PubMed]
  110. Tatu, A.L.; Nadasdy, T.; Bujoreanu, F.C. Familial clustering of COVID-19 skin manifestations. Dermatol. Ther. 2020, 33, e14181. [Google Scholar] [CrossRef]
  111. Calderon, L.A.; Sobrinho, J.C.; Zaqueo, K.D.; de Moura, A.A.; Grabner, A.N.; Mazzi, M.V.; Marcussi, S.; Nomizo, A.; Fernandes, C.F.; Zuliani, J.P.; et al. Antitumoral activity of snake venom proteins: New trends in cancer therapy. Biomed. Res. Int. 2014, 2014, 203639. [Google Scholar] [CrossRef]
  112. Ebrahim, K.; Shirazi, F.H.; Mirakabadi, A.Z.; Vatanpour, H. Cobra venom cytotoxins; apoptotic or necrotic agents? Toxicon 2015, 108, 134–140. [Google Scholar] [CrossRef] [PubMed]
  113. Lafnoune, A.; Lee, S.Y.; Heo, J.Y.; Gourja, I.; Darkaoui, B.; Abdelkafi-Koubaa, Z.; Chgoury, F.; Daoudi, K.; Chakir, S.; Cadi, R.; et al. Anti-Cancer Effect of Moroccan Cobra Naja haje Venom and Its Fractions against Hepatocellular Carcinoma in 3D Cell Culture. Toxins 2021, 13, 402. [Google Scholar] [CrossRef] [PubMed]
  114. Wang, S.Z.; Xu, Y.L.; Zhu, Q.; Kou, J.Q.; Qin, Z.H. Cobrotoxin from Naja naja atra Venom Ameliorates Adriamycin Nephropathy in Rats. Evid.-Based Complement. Altern. Med. 2015, 2015, 450581. [Google Scholar] [CrossRef]
  115. Ding, Z.H.; Xu, L.M.; Wang, S.Z.; Kou, J.Q.; Xu, Y.L.; Chen, C.X.; Yu, H.P.; Qin, Z.H.; Xie, Y. Ameliorating Adriamycin-Induced Chronic Kidney Disease in Rats by Orally Administrated Cardiotoxin from Naja naja atra Venom. Evidence-Based Complement. Altern. Med. 2014, 2014, 621756. [Google Scholar] [CrossRef] [PubMed]
  116. Cui, K.; Kou, J.Q.; Gu, J.H.; Han, R.; Wang, G.; Zhen, X.; Qin, Z.H. Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress. BMC Complement. Altern. Med. 2014, 14, 461. [Google Scholar] [CrossRef]
  117. Zhu, J.; Cui, K.; Kou, J.; Wang, S.; Xu, Y.; Ding, Z.; Han, R.; Qin, Z. Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice. Evid.-Based Complement. Altern. Med. 2014, 2014, 969482. [Google Scholar] [CrossRef]
  118. Veberic, R.; Mikulic-Petkovsek, M. Chapter 11-Phytochemical Composition of Common Fig (Ficus carica L.) Cultivars. In Nutritional Composition of Fruit Cultivars; Simmonds, M.S.J., Preedy, V.R., Eds.; Academic Press: San Diego, CA, USA, 2016; pp. 235–255. [Google Scholar] [CrossRef]
  119. Simsek, E.; Kilic, D.; Caliskan, O. Phenotypicvariation of figgenotypes (Ficus carica L.) in theeasternMediterranean of Turkey. Genetika 2020, 52, 957–972. [Google Scholar] [CrossRef]
  120. Janick, J.; Paris, H.S.; Parrish, D.C. The Cucurbits of Mediterranean Antiquity: Identification of Taxa from Ancient Images and Descriptions. Ann. Bot. 2007, 100, 1441–1457. [Google Scholar] [CrossRef]
  121. Arvaniti, O.S.; Samaras, Y.; Gatidou, G.; Thomaidis, N.S.; Stasinakis, A.S. Review on fresh and dried figs: Chemical analysis and occurrence of phytochemical compounds, antioxidant capacity and health effects. Food Res. Int. 2019, 119, 244–267. [Google Scholar] [CrossRef]
  122. Mori, K.; Shirasawa, K.; Nogata, H.; Hirata, C.; Tashiro, K.; Habu, T.; Kim, S.; Himeno, S.; Kuhara, S.; Ikegami, H. Identification of RAN1 orthologue associated with sex determination through whole genome sequencing analysis in fig (Ficus carica L.). Sci. Rep. 2017, 7, 41124. [Google Scholar] [CrossRef]
  123. Schwab, W.; Davidovich-Rikanati, R.; Lewinsohn, E. Biosynthesis of plant-derived flavor compounds. Plant J. 2008, 54, 712–732. [Google Scholar] [CrossRef] [PubMed]
  124. Badgujar, S.B.; Patel, V.V.; Bandivdekar, A.H.; Mahajan, R.T. Traditional uses, phytochemistry and pharmacology of Ficus carica: A review. Pharm. Biol. 2014, 52, 1487–1503. [Google Scholar] [CrossRef] [PubMed]
  125. Rezagholizadeh, L.; Aghamohammadian, M.; Oloumi, M.; Banaei, S.; Mazani, M.; Ojarudi, M. Inhibitory effects of Ficus carica and Olea europaea on pro-inflammatory cytokines: A review. Iran. J. Basic. Med. Sci. 2022, 25, 268–275. [Google Scholar] [CrossRef] [PubMed]
  126. Abe, T.; Koyama, Y.; Nishimura, K.; Okiura, A.; Takahashi, T. Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial. Nutrients 2022, 14, 4470. [Google Scholar] [CrossRef]
  127. Elghareeb, M.M.; Elshopakey, G.E.; Hendam, B.M.; Rezk, S.; Lashen, S. Synergistic effects of Ficus carica extract and extra virgin olive oil against oxidative injury, cytokine liberation, and inflammation mediated by 5-Fluorouracil in cardiac and renal tissues of male albino rats. Environ. Sci. Pollut. Res. 2021, 28, 4558–4572. [Google Scholar] [CrossRef]
  128. Takahashi, T.; Okiura, A.; Saito, K.; Kohno, M. Identification of phenylpropanoids in fig (Ficus carica L.) leaves. J. Agric. Food Chem. 2014, 62, 10076–10083. [Google Scholar] [CrossRef]
  129. Ammar, S.; del Mar Contreras, M.; Belguith-Hadrich, O.; Segura-Carretero, A.; Bouaziz, M. Assessment of the distribution of phenolic compounds and contribution to the antioxidant activity in Tunisian fig leaves, fruits, skins and pulps using mass spectrometry-based analysis. Food Funct. 2015, 6, 3663–3677. [Google Scholar] [CrossRef]
  130. Belguith-Hadriche, O.; Ammar, S.; Contreras, M.d.M.; Fetoui, H.; Segura-Carretero, A.; El Feki, A.; Bouaziz, M. HPLC-DAD-QTOF-MS profiling of phenolics from leaf extracts of two Tunisian fig cultivars: Potential as a functional food. Biomed. Pharmacother. 2017, 89, 185–193. [Google Scholar] [CrossRef]
  131. Singab, A.N.; Ayoub, N.A.; Ali, E.N.; Mostafa, N.M. Antioxidant and hepatoprotective activities of Egyptian moraceous plants against carbon tetrachloride-induced oxidative stress and liver damage in rats. Pharm. Biol. 2010, 48, 1255–1264. [Google Scholar] [CrossRef]
  132. Slatnar, A.; Klancar, U.; Stampar, F.; Veberic, R. Effect of drying of figs (Ficus carica L.) on the contents of sugars, organic acids, and phenolic compounds. J. Agric. Food Chem. 2011, 59, 11696–11702. [Google Scholar] [CrossRef]
  133. Çalişkan, O.; AytekinPolat, A. Phytochemicaland antioxidant properties of selectedfig (Ficus carica L.) accessionsfromtheeasternMediterraneanregion of Turkey. Sci. Hortic. 2011, 128, 473–478. [Google Scholar] [CrossRef]
  134. Solomon, A.; Golubowicz, S.; Yablowicz, Z.; Grossman, S.; Bergman, M.; Gottlieb, H.E.; Altman, A.; Kerem, Z.; Flaishman, M.A. Antioxidant activities and anthocyanin content of fresh fruits of common fig (Ficus carica L.). J. Agric. Food Chem. 2006, 54, 7717–7723. [Google Scholar] [CrossRef] [PubMed]
  135. Vallejo, F.; Marín, J.G.; Tomás-Barberán, F.A. Phenolic Compound Content of Fresh and Dried Figs (Ficus carica L.). Food Chem. 2012, 130, 485–492. [Google Scholar] [CrossRef]
  136. Palmeira, L.; Pereira, C.; Dias, M.I.; Abreu, R.M.V.; Corrêa, R.C.G.; Pires, T.C.S.P.; Alves, M.J.; Barros, L.; Ferreira, I.C.F.R. Nutritional, Chemical and Bioactive Profiles of Different Parts of a Portuguese Common Fig (Ficus carica L.) Variety. Food Res. Int. 2019, 126, 108572. [Google Scholar] [CrossRef]
  137. Vinson, J.A. The Functional Food Properties of Figs. Cereal Foods World 1999, 44, 82–87. [Google Scholar]
  138. Ajmal, M.; Arshad, M.U.; Saeed, F.; Ahmed, T.; Khan, A.U.; Bader-ul-Ain, H.; Suleria, H.A.R. Exploring the Nutritional Characteristics of Different Parts of Fig in Relation to Hypoglycemic Potential. Pak. J. Life Soc. Sci. 2016, 14, 115–122. [Google Scholar]
  139. Ara, I. Comparative Antioxidative and Antidiabetic Activities of Ficus carica Pulp, Peel and Leaf and Their Correlation with Phytochemical Contents. Open Access J. Pharm. Res. 2020, 4, 1–8. [Google Scholar] [CrossRef]
  140. Ren, Y.; Song, X.; Tan, L.; Guo, C.; Wang, M.; Liu, H.; Cao, Z.; Li, Y.; Peng, C. A Review of the Pharmacological Properties of Psoralen. Front. Pharmacol. 2020, 11, 571535. [Google Scholar] [CrossRef] [PubMed]
  141. Doppalapudi, S.; Jain, A.; Chopra, D.K.; Khan, W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur. J. Pharm. Sci. 2017, 96, 515–529. [Google Scholar] [CrossRef]
  142. Bianca, M.; Mihaela, D.R.; Laurentiu, T.A.; Dumitriu Buzia, O. Bioactive compounds from Piper nigrum—A new hope for vitiligo treatment? J. Am. Acad. Dermatol. 2019, 81, AB26. [Google Scholar]
  143. Abdel-Aty, A.M.; Hamed, M.B.; Salama, W.H.; Ali, M.M.; Fahmy, A.S.; Mohamed, S.A. Ficus carica, Ficus sycomorus and Euphorbiatirucalli latex extracts: Phytochemical screening, antioxidant andcytotoxicproperties. Biocatal. Agric. Biotechnol. 2019, 20, 101199. [Google Scholar] [CrossRef]
  144. Hajam, T.A.; Saleem, H. Phytochemistry, biological activities, industrial and traditional uses of fig (Ficus carica): A review. Chem. Interact. 2022, 368, 110237. [Google Scholar] [CrossRef] [PubMed]
  145. Camero, M.; Marinaro, M.; Lovero, A.; Elia, G.; Losurdo, M.; Buonavoglia, C.; Tempesta, M. In vitro antiviral activity of Ficus carica latex against caprine herpesvirus-1. Nat. Prod. Res. 2014, 28, 2031–2035. [Google Scholar] [CrossRef] [PubMed]
  146. Salma, S.; Shamsi, Y.; Ansari, S.; Nikhat, S. Ficus carica L.: A panacea of nutritional and medicinal benefits. Cellmed 2020, 10, 1. [Google Scholar]
  147. Zhang, Y.; Li, Y.; Ma, P.; Chen, J.; Xie, W. Ficus carica leaves extract inhibited pancreatic β-cellapoptosisbyinhibiting AMPK/JNK/caspase-3 signalingpathwayandantioxidation. Biomed. Pharmacother. 2020, 122, 109689. [Google Scholar] [CrossRef]
  148. Ao, C.; Li, A.; Elzaawely, A.A.; Xuan, T.D.; Tawata, S. Evaluation of antioxidant andantibacterialactivities of Ficus microcarpa L. fil. Extract. Food Control 2008, 19, 940–948. [Google Scholar] [CrossRef]
  149. Abdel-Hameed, E.S.S. Total phenoliccontentsandfree radical scavengingactivity of certainEgyptian Ficus speciesleafsamples. Food Chem. 2009, 114, 1271–1277. [Google Scholar] [CrossRef]
  150. Khan, H.; Akhtar, N.; Ali, A. Effects of Cream Containing Ficus carica L. Fruit Extract on Skin Parameters: In vivo Evaluation. Indian J. Pharm. Sci. 2014, 76, 560–564. [Google Scholar] [PubMed] [PubMed Central]
  151. Gond, N.Y.; Khadabadi, S.S. Hepatoprotective activity of Ficus carica leaf extract on rifampicin-induced hepatic damage in rats. Indian J. Pharm. Sci. 2008, 70, 364–366. [Google Scholar] [CrossRef]
  152. Jeong, M.-R.; Kim, H.-Y.; Cha, J.-D. Antimicrobial activity of methanol extract from Ficus carica leaves against oral bacteria. J. Bacteriol. Virol. 2009, 39, 97–102. [Google Scholar] [CrossRef]
  153. Aref, H.L.; Salah, K.B.H.; Chaumont, J.P.; Fekih, A.; Aouni, M.; Said, K. In vitro antimicrobial activity of four Ficus carica latex fractions against resistant human pathogens (antimicrobial activity of Ficus carica latex). Pak. J. Pharm. Sci. 2010, 23, 53–58. [Google Scholar] [PubMed]
  154. Mawa, S.; Husain, K.; Jantan, I. Ficus carica L. (Moraceae): Phytochemistry, Traditional Uses and Biological Activities. Evid. Based Complement. Alternat Med. 2013, 2013, 974256. [Google Scholar] [CrossRef] [PubMed]
  155. Michalak, M.; Pierzak, M.; Kręcisz, B.; Suliga, E. Bioactive Compounds for Skin Health: A Review. Nutrients 2021, 13, 203. [Google Scholar] [CrossRef] [PubMed]
  156. Wild, C.P. Complementing the genome with an “exposome”: The outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol. Biomark. Prev. 2005, 14, 1847–1850. [Google Scholar] [CrossRef]
  157. Vileikyte, L. Stress and wound healing. Clin. Dermatol. 2007, 25, 49–55. [Google Scholar] [CrossRef]
  158. Santacruz-Perez, C.; Paulo Newton Tonolli, P.; Ravagnani, F.G.; Baptista, F.S. Photochemistry of Lipofuscin and the Interplay of UVA and Visible Light in Skin Photosensitivity. Photochem. Photophysics 2017, 89–102. [Google Scholar] [CrossRef]
  159. Romana-Souza, B.; Santos Lima-Cezar, G.; Monte-Alto-Costa, A. Psychological stress-induced catecholamines accelerates cutaneous aging in mice. Mech. Ageing Dev. 2015, 152, 63–73. [Google Scholar] [CrossRef]
  160. George, J.; Sneed, K.; Pathak, Y. The Skin Aging Process and Anti-Aging Strategies. Biomed. J. Sci. Tech. Res. 2022, 42, 33377–33386. [Google Scholar] [CrossRef]
  161. Russell-Goldman, E.; Murphy, G.F. The Pathobiology of Skin Aging New Insights into an Old Dilemma. Am. J. Pathol. 2020, 190, 1356–1369. [Google Scholar] [CrossRef]
  162. Gębalski, J.; Graczyk, F.; Załuski, D. Paving the way towards effective plant-based inhibitors of hyaluronidase and tyrosinase: A critical review on a structure–activity relationship. J. Enzyme Inhib. Med. Chem. 2022, 37, 1120–1195. [Google Scholar] [CrossRef]
  163. Thring, T.S.; Hili, P.; Naughton, D.P. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. BMC Complement. Altern. Med. 2009, 9, 27. [Google Scholar] [CrossRef] [PubMed]
  164. Dinu, M.; Tatu, A.L.; Cocoș, D.I.; Nwabudike, L.C.; Chirilov, A.M.; Stefan, C.S.; Earar, K.; Dumitriu Buzia, O. Natural Sources of Therapeutic Agents Used in Skin Conditions. Life 2024, 14, 492. [Google Scholar] [CrossRef]
  165. Shah, S.; Gupta, A.; Karne, S.P.; Kamble, S.; Shinde, B. Anti-inflammatory activity of sting protein from Apis mellifera. Int. J. Life Sci. Sci. Res. 2017, 3, 914–919. [Google Scholar] [CrossRef]
  166. Han, S.M.; Kim, J.M.; Hong, I.P.; Woo, S.O.; Kim, S.G.; Jang, H.R.; Pak, S.C. Antibacterial activity and antibiotic-enhancing effects of honeybee venom against methicillin-resistant Staphylococcus aureus. Molecules 2016, 21, 79. [Google Scholar] [CrossRef]
  167. Kim, H.; Park, S.Y.; Lee, G. Potential Therapeutic Applications of Bee Venom on Skin Disease and Its Mechanisms: A Literature Review. Toxins 2019, 11, 374. [Google Scholar] [CrossRef] [PubMed]
  168. Dumitru, C.D.; Neacsu, I.A.; Grumezescu, A.M.; Andronescu, E. Bee-Derived Products: Chemical Composition and Applications in Skin Tissue Engineering. Pharmaceutics 2022, 14, 750. [Google Scholar] [CrossRef] [PubMed]
  169. Amin, M.A.; Abdel-Raheem, I.T. Accelerated wound healing and anti-inflammatory effects of physically cross linked polyvinyl alcohol-chitosan hydrogel containing honey bee venom in diabetic rats. Arch. Pharm. Res. 2014, 37, 1016–1031. [Google Scholar] [CrossRef] [PubMed]
  170. Nwabudike, L.C.; Tatu, A.L. Magistral Prescription With Silver Nitrate and Peru Balsam in Difficult-to-Heal Diabetic Foot Ulcers. Am. J. Ther. 2018, 25, e679–e680. [Google Scholar] [CrossRef]
  171. Buzia, O.D.; Dima, C.; Dima, S. Preparation and characterization of chitosan microspheres for vancomycin delivery. Rev. Farm. 2015, 63, 897–902. [Google Scholar]
  172. Wang, Z.; Gao, S.; Zhang, W.; Gong, H.; Xu, K.; Luo, C.; Zhi, W.; Chen, X.; Li, J.; Weng, J. Polyvinyl alcohol/chitosan composite hydrogels with sustained release of traditional Tibetan medicine for promoting chronic diabetic wound healing. Biomater. Sci. 2021, 9, 3821–3829. [Google Scholar] [CrossRef]
  173. Badr, G.; Hozzein, W.N.; Badr, B.M.; Al Ghamdi, A.; Saad Eldien, H.M.; Garraud, O. Bee Venom Accelerates Wound Healing in Diabetic Mice by Suppressing Activating Transcription Factor-3 (ATF-3) and Inducible Nitric Oxide Synthase (iNOS)-Mediated Oxidative Stress and Recruiting Bone Marrow-Derived Endothelial Progenitor Cells. J. Cell Physiol. 2016, 231, 2159–2171. [Google Scholar] [CrossRef] [PubMed]
  174. Han, S.M.; Lee, K.G.; Pak, S.C. Effects of cosmetics containing purified honeybee (Apis mellifera L.) venom on acne vulgaris. J. Integr. Med. 2013, 11, 320–326. [Google Scholar] [CrossRef]
  175. Han, S.M.; Pak, S.C.; Nicholls, Y.M.; Macfarlane, N. Evaluation of anti-acne property of purified bee venom serum in humans. J. Cosmet. Dermatol. 2016, 15, 324–329. [Google Scholar] [CrossRef] [PubMed]
  176. An, H.J.; Lee, W.R.; Kim, K.H.; Kim, J.Y.; Lee, S.J.; Han, S.M.; Lee, K.G.; Lee, C.K.; Park, K.K. Inhibitory effects of bee venom on propionibacterium acnes-induced inflammatory skin disease in an animal model. Int. J. Mol. Med. 2014, 34, 1341–1348. [Google Scholar] [CrossRef]
  177. Lee, W.R.; Kim, K.H.; An, H.J.; Kim, J.Y.; Chang, Y.C.; Chung, H.; Park, Y.Y.; Lee, M.L.; Park, K.K. The protective effects of melittin on propionibacterium acnes-induced inflammatory responses in vitro and in vivo. J. Investig. Dermatol. 2014, 134, 1922–1930. [Google Scholar] [CrossRef]
  178. Gu, H.; Han, S.M.; Park, K.K. Therapeutic Effects of Apamin as a Bee Venom Component for Non-Neoplastic Disease. Toxins 2020, 12, 195. [Google Scholar] [CrossRef]
  179. Jeon, S.; Kim, N.H.; Koo, B.S.; Lee, H.J.; Lee, A.Y. Bee venom stimulates human melanocyte proliferation, melanogenesis, dendricity and migration. Exp. Mol. Med. 2007, 39, 603–613. [Google Scholar] [CrossRef] [PubMed]
  180. Hegazi, A.G.; Abd Raboh, F.A.; Ramzy, N.E.; Shaaban, D.M.; Khader, D.Y. Bee venom and propolis as new treatment modality in patients with localized plaque psoriases. Int. Res. J. Med. Med. Sci. 2013, 1, 27–33. [Google Scholar]
  181. Eltaher, S.; Mohammed, G.F.; Younes, S.; Elakhras, A. Efficacy of the apitherapy in the treatment of recalcitrant localized plaque psoriasis and evaluation of tumor necrosis factor-alpha (TNF-α) serum level: A double-blind randomized clinical trial. J. Dermatolog Treat. 2015, 26, 335–339. [Google Scholar] [CrossRef]
  182. Kopczyńska, D.; Klasik-Ciszewska, S.; Duda-Grychtoł, K. Bee products in skin care. Med. Rodz. 2018, 21, 48–52. [Google Scholar] [CrossRef]
  183. Han, S.M.; Hong, I.P.; Woo, S.O.; Chun, S.N.; Park, K.K.; Nicholls, Y.M.; Pak, S.C. The beneficial effects of honeybee-venom serum on facial wrinkles in humans. Clin. Interv. Aging. 2015, 10, 1587–1592. [Google Scholar] [CrossRef] [PubMed]
  184. Parente, M.; Gámbaro, A.; Roselli, T.; Capdebila, P. Clinical evaluation of the efficacy of bee venom as cosmetic active. J. Dermat. Cosmetol. 2020, 4, 152–157. [Google Scholar] [CrossRef]
  185. Lee, H.; Bae, S.K.; Pyo, M.-J.; Heo, Y.; Kim, C.G.; Kang, C.; Kim, E. Anti-wrinkle effect of PLA2-free bee venom against UVB-irradiated human skin cells. J. Agric. Life Sci. 2015, 49, 125–135. [Google Scholar] [CrossRef]
  186. Tanuğur Samancı, A.E.; Kekeçoğlu, M. Development of a cream formulation containing bee venom and other bee products. J. Cosmet. Dermatol. 2022, 21, 4913–4920. [Google Scholar] [CrossRef]
  187. Park, S.; Erdogan, S.; Hwang, D.; Hwang, S.; Han, E.H.; Lim, Y.H. Bee venom promotes hair growth in association with inhibiting 5α-reductase expression. Biol. Pharm. Bull. 2016, 39, 1060–1068. [Google Scholar] [CrossRef] [PubMed]
  188. Ngoc, L.T.N.; Moon, J.-Y.; Lee, Y.-C. Insights into Bioactive Peptides in Cosmetics. Cosmetics 2023, 10, 111. [Google Scholar] [CrossRef]
  189. Prokopowicz, M.; Różycki, K.M. Innovation in cosmetics. World Sci. News 2017, 72, 448–456. [Google Scholar]
  190. Yadav, A.R.; Mohite, S.K. Potential role of peptides for development of cosmeceutical skin products. Res. J. Top. Cosmet. Sci. 2020, 11, 77–82. [Google Scholar] [CrossRef]
  191. Samy, R.P.; Sethi, G.; Lim, L.H. A brief update on potential molecular mechanisms underlying antimicrobial and wound-healing potency of snake venom molecules. Biochem. Pharmacol. 2016, 115, 1–9. [Google Scholar] [CrossRef]
  192. Solano, F. Photoprotection and Skin Pigmentation: Melanin-Related Molecules and Some Other New Agents Obtained from Natural Sources. Molecules 2020, 25, 1537. [Google Scholar] [CrossRef]
  193. Skarupova, D.; Vostalova, J.; Rajnochova Svobodova, A. Ultraviolet A protective potential of plant extracts and phytochemicals. Biomed. Pap. Med. Fac. Palacky Univ. Olomouc 2020, 164, 1–22. [Google Scholar] [CrossRef] [PubMed]
  194. Torres-Contreras, A.M.; Garcia-Baeza, A.; Vidal-Limon, H.R.; Balderas-Renteria, I.; Ramírez-Cabrera, M.A.; Ramirez-Estrada, K. Plant Secondary Metabolites against Skin Photodamage: Mexican Plants, a Potential Source of UV-Radiation Protectant Molecules. Plants 2022, 11, 220. [Google Scholar] [CrossRef] [PubMed]
  195. Garg, A.; Chren, M.M.; Sands, L.P.; Matsui, M.S.; Marenus, K.D.; Feingold, K.R.; Elias, P.M. Psychological stress perturbs epidermal permeability barrier homeostasis: Implications for the pathogenesis of stress-associated skin disorders. Arch. Dermatol. 2001, 137, 53–59. [Google Scholar] [CrossRef]
  196. Zhang, L.; Li, W.H.; Anthonavage, M.; Pappas, A.; Rossetti, D.; Cavender, D.; Seiberg, M.; Eisinger, M. Melanocortin-5 receptor and sebogenesis. Eur. J. Pharmacol. 2011, 660, 202–206. [Google Scholar] [CrossRef]
  197. El-Shobaki, F.A.; El-Bahay, A.M.; Esmail, R.S. Effects of figs fruit (Ficus carica L.) and its leaves on hyperglycemia in alloxan diabetic rats. World J. Diary food Sci. 2010, 5, 47–57. [Google Scholar]
  198. Jang, S.; Kelley, K.W.; Johnson, R.W. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc. Natl. Acad. Sci. USA 2008, 105, 7534–7539. [Google Scholar] [CrossRef]
  199. Vaya, J.; Mahmood, S. Flavonoid content in leaf extracts of the fig (Ficus carica L.), carob (Ceratonia siliqua L.) and pistachio (Pistacia lentiscus L.). Biofactors 2006, 28, 169–175. [Google Scholar] [CrossRef]
  200. Cho, U.M.; Choi, D.H.; Yoo, D.S. Inhibitory Effect of Ficin Derived from Fig Latex on Inflammation and Melanin Production in Skin Cells. Biotechnol. Bioprocess Eng. 2019, 24, 288–297. [Google Scholar] [CrossRef]
  201. Devaraj, K.B.; Kumar, P.R.; Prakash, V. Purification, characterization, and solvent-induced thermal stabilization of ficin from Ficus carica. J. Agric. Food Chem. 2008, 56, 11417–11423. [Google Scholar] [CrossRef]
  202. Chen, Y.; Lyga, J. Brain-skin connection: Stress, inflammation and skin aging. Inflamm. Allergy Drug Targets 2014, 13, 177–190. [Google Scholar] [CrossRef]
  203. Chawla, A.; Kaur, R.; Sharma, A.K. Ficus carica Linn. A review on its pharmacognostic, phytochemical and pharmacological aspects. Int. J. Pharmacol. Res. 2012, 1, 215–232. [Google Scholar]
  204. Ali, B.; Mujeeb, M.; Aeri, V.; Mir, S.R.; Faiyazuddin, M.; Shakeel, F. Anti-inflammatory and antioxidant activity of Ficus carica Linn. leaves. Nat. Prod. Res. 2012, 26, 460–465. [Google Scholar] [CrossRef] [PubMed]
  205. Dini, I.; Falanga, D.; Di Lorenzo, R.; Tito, A.; Carotenuto, G.; Zappelli, C.; Grumetto, L.; Sacchi, A.; Laneri, S.; Apone, F. An Extract from Ficus carica Cell Cultures Works as an Anti-Stress Ingredient for the Skin. Antioxidants 2021, 10, 515. [Google Scholar] [CrossRef] [PubMed]
  206. Verschooten, L.; Claerhout, S.; Van Laethem, A.; Agostinis, P.; Garmyn, M. New strategies of photoprotection. Photochem. Photobiol. 2006, 82, 1016–1023. [Google Scholar] [CrossRef]
  207. Wagner, H. Multitarget therapy--the future of treatment for more than just functional dyspepsia. Phytomedicine 2006, 13, 122–129. [Google Scholar] [CrossRef]
  208. Ghimeray, A.K.; Jung, U.S.; Lee, H.Y.; Kim, Y.H.; Ryu, E.K.; Chang, M.S. In vitro antioxidant, collagenase inhibition, and in vivo anti-wrinkle effects of combined formulation containing Punica granatum, Ginkgo biloba, Ficus carica, and Morus alba fruits extract. Clin. Cosmet. Investig. Dermatol. 2015, 8, 389–396. [Google Scholar] [CrossRef]
  209. Dal Belo, S.E.; Gaspar, L.R.; Maia Campos, P.M. Photoprotective effects of topical formulations containing a combination of Ginkgo biloba and green tea extracts. Phytother. Res. 2011, 25, 1854–1860. [Google Scholar] [CrossRef]
  210. Pacheo-Palencia, L.A.; Noratto, G.; Hingorani, L.; Talcott, S.T.; Mertens-Talcott, S.U. Protective effects of standardized pomegranate (Punica granatum L.) polyphenolic extract in ultraviolet-irradiated human skin fibroblasts. J. Agric. Food Chem. 2008, 56, 8434–8441. [Google Scholar] [CrossRef]
  211. Aslam, M.N.; Lansky, E.P.; Varani, J. Pomegranate as a cosmeceutical source: Pomegranate fractions promote proliferation and procollagen synthesis and inhibit matrix metalloproteinase-1 production in human skin cells. J. Ethnopharmacol. 2006, 103, 311–318. [Google Scholar] [CrossRef]
  212. Sirisha, N.; Sreenivasulu, M.; Sangeeta, K.; Madhusudhana Chetty, C. Antioxidant properties of Ficus species—A review. Int. J. Pharm. Tech. Res. 2010, 2, 2174–2182. [Google Scholar]
  213. Ercisli, S.; Orhan, E. Chemical composition of white (Morus alba), red (Morus rubra) and black (Morus nigra) mulberry fruits. Food Chem. 2007, 103, 1380–1384. [Google Scholar] [CrossRef]
  214. Zafar, M.S.; Faqir Muhammad, F.M.; Ijaz Javed, I.J.; Masood Akhtar, M.A.; Tanweer Khaliq, T.K.; Bilal Aslam, B.A.; Abdul Waheed, A.W.; Riffat Yasmin, R.Y.; Hira Zafar, H.Z. White Mulberry (Morus alba): A brief phytochemical and pharmacological evaluation account. Int. J. Agri Biol. 2013, 15, 612–620. [Google Scholar]
  215. Raffetto, J.D.; Khalil, R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75, 346–359. [Google Scholar] [CrossRef]
  216. Moore, A.R.; Willoughby, D. A The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995, 101, 387–389. [Google Scholar] [CrossRef]
  217. Aburjai, T.; Natsheh, F.M. Plants used in cosmetics. Phytother. Res. 2003, 17, 987–1000. [Google Scholar] [CrossRef] [PubMed]
  218. Ghanbari, A.; Le Gresley, A.; Naughton, D.; Kuhnert, N.; Sirbu, D.; Ashrafi, G.H. Biologicalactivities of Ficus carica latex for potentialtherapeutics in HumanPapillomavirus (HPV) related cervical cancers. Sci. Rep. 2019, 9, 19258. [Google Scholar] [CrossRef]
  219. Rinnerthaler, M.; Bischof, J.; Streubel, M.K.; Trost, A.; Richter, K. Oxidative Stress in Aging Human Skin. Biomolecules 2015, 5, 545–589. [Google Scholar] [CrossRef] [PubMed]
  220. Feingold, K.R. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J. Lipid Res. 2007, 48, 2531–2546. [Google Scholar] [CrossRef]
  221. McMullen, R.L.; Dell’Acqua, G. History of Natural Ingredients in Cosmetics. Cosmetics 2023, 10, 71. [Google Scholar] [CrossRef]
  222. Fonseca-Santos, B.; Corrêa, M.; Chorilli, M. Sustainability, natural, and organic cosmetics: Consumer, products, efficacy, toxicological, and regulatory considerations. Braz. J. Pharm. Sci. 2015, 51, 17–26. [Google Scholar] [CrossRef]
  223. Klaschka, U. Natural personal care products—Analysis of ingredient lists and legal situation. Environ. Sci. Eur. 2016, 28, 1–14. [Google Scholar] [CrossRef] [PubMed]
  224. Rusmil MR, A.; Othman, I.; Mohamad CA, C. The use of venom and venom-derived products in medicine and cosmetics: The ethical issues from Islamic perspective. Int. Med. J. Malays. 2018, 17, 1–6. [Google Scholar] [CrossRef]
  225. Ali, M. Studies on bee venom its medical uses. Int. J. Adv. Res. Technol. 2012, 1, 69–83. [Google Scholar]
  226. Ullah, A.; Aldakheel, F.M.; Anjum, S.I.; Raza, G.; Khan, S.A.; Tlak Gajger, I. Pharmacological properties and therapeutic potential of honey bee venom. Saudi Pharm. J. 2023, 31, 96–109. [Google Scholar] [CrossRef]
  227. Schumacher, M.J.; Tveten, M.S.; Egen, N.B. Rate and quantity of delivery of venom from honeybee stings. J. Allergy Clin. Immunol. 1994, 93, 831–835. [Google Scholar] [CrossRef]
  228. Bonifazi, F.; Jutel, M.; Biló, B.M.; Birnbaum, J.; Muller, U. The EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice. Allergy 2005, 60, 1459–1470. [Google Scholar] [CrossRef] [PubMed]
  229. Han, S.M.; Lee, G.G.; Park, K.K. Skin sensitization study of bee venom (Apis mellifera L.) in guinea pigs. Toxicol. Res. 2012, 28, 1–4. [Google Scholar] [CrossRef] [PubMed]
  230. Carpena, M.; Nuñez-Estevez, B.; Soria-Lopez, A.; Simal-Gandara, J. Bee Venom: An Updating Review of Its Bioactive Molecules and Its Health Applications. Nutrients 2020, 12, 3360. [Google Scholar] [CrossRef] [PubMed]
  231. Parveen, G.; Khan, M.F.; Ali, H.; Ibrahim, T.; Shah, R. Determination of Lethal Dose (LD50) of Venom of four Different Poisonous Snakes found in Pakistan. J. Biochem. Mol. Biol. 2017, 3, e18. [Google Scholar] [CrossRef]
  232. Angeletti, R.H. Nerve growth factor from cobra venom. Proc. Natl. Acad. Sci. USA 1970, 65, 668–674. [Google Scholar] [CrossRef]
  233. Awobajo, F.; Omorodion-Osagie, E.; Olatunji-Bello, I.; Adegoke, O.; Adeleke, T. Acute oral toxicity test and phytochemistry of some west African medicinal plants. Niger. Q. J. Hosp. Med. 2009, 19, 1. [Google Scholar] [CrossRef] [PubMed]
  234. Aghel, N.; Kalantari, H.; Rezazadeh, S. Hepatoprotective effect of Ficus carica leaf extract on mice intoxicated with carbon tetrachloride. Iran. J. Pharm. Res. 2011, 10, 63–68. [Google Scholar] [PubMed] [PubMed Central]
  235. Kebal, L.; Djebli, N.; Pokajewicz, K.; Mostefa, N.; Wieczorek, P.P. Antioxidant Activity and Effectiveness of Fig Extract in Counteracting Carbon Tetrachloride-Induced Oxidative Damage in Rats. Molecules. 2024, 29, 1997. [Google Scholar] [CrossRef] [PubMed]
  236. Ghafoor, A.; Tahir, M.; Lone, K.P.; Faisal, B.; Latif, W. The effect of Ficus carica L. (Anjir) leaf extract on gentamicin induced nephrotoxicity in adult male albino mice. J. Ayub Med. Coll. Abbottabad. 2015, 27, 398–401. [Google Scholar] [PubMed]
  237. Saeed, M.A.; Sabir, A.W. Irritant potential of triterpenoids from Ficus carica leaves. Fitoterapia 2002, 73, 417–420. [Google Scholar] [CrossRef] [PubMed]
  238. Sadek, K.M.; Shib, N.A.; Taher, E.S.; Rashed, F.; Shukry, M.; Atia, G.A.; Taymour, N.; El-Nablaway, M.; Ibrahim, A.M.; Ramadan, M.M.; et al. Harnessing the power of bee venom for therapeutic and regenerative medical applications: An updated review. Front. Pharmacol. 2024, 15, 1412245. [Google Scholar] [CrossRef]
  239. Dini, I.; Mancusi, A. Food Peptides for the Nutricosmetic Industry. Antioxidants 2023, 12, 788. [Google Scholar] [CrossRef]
  240. Municoy, S.; Alvarez Echazu, M.I.; Antezana, P.E.; Galdopórpora, J.M.; Olivetti, C.; Mebert, A.M.; Foglia, M.L.; Tuttolomondo, M.V.; Alvarez, G.S.; Hardy, J.G.; et al. Stimuli-responsive materials for tissue engineering and drug delivery. Int. J. Mol. Sci. 2020, 21, 4724. [Google Scholar] [CrossRef]
  241. Kim, B.; Cho, H.E.; Moon, S.H.; Ahn, H.J.; Bae, S.; Cho, H.D.; An, S. Transdermal delivery systems in cosmetics. Biomed. Dermatol. 2020, 4, 10. [Google Scholar] [CrossRef]
  242. Yu, Y.Q.; Yang, X.; Wu, X.F.; Fan, Y.B. Enhancing permeation of drug molecules across the skin via delivery in nanocarriers: Novel strategies for effective transdermal applications. Front. Bioeng. Biotechnol. 2021, 9, 200. [Google Scholar] [CrossRef]
  243. Dumitriu Buzia, O.; Păduraru, A.M.; Stefan, C.S.; Dinu, M.; Cocoș, D.I.; Nwabudike, L.C.; Tatu, A.L. Strategies for Improving Transdermal Administration: New Approaches to Controlled Drug Release. Pharmaceutics 2023, 15, 1183. [Google Scholar] [CrossRef] [PubMed]
  244. Cocoș, D.I.; Dumitriu Buzia, O.; Tatu, A.L.; Dinu, M.; Nwabudike, L.C.; Stefan, C.S.; Earar, K.; Galea, C. Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity. Pharmaceutics 2024, 16, 626. [Google Scholar] [CrossRef] [PubMed]
  245. Fytianos, G.; Rahdar, A.; Kyzas, G.Z. Nanomaterials in Cosmetics: Recent Updates. Nanomaterials 2020, 10, 979. [Google Scholar] [CrossRef] [PubMed]
  246. Gupta, V.; Mohapatra, S.; Mishra, H.; Farooq, U.; Kumar, K.; Ansari, M.J.; Aldawsari, M.F.; Alalaiwe, A.S.; Mirza, M.A.; Iqbal, Z. Nanotechnology in Cosmetics and Cosmeceuticals-A Review of Latest Advancements. Gels 2022, 8, 173. [Google Scholar] [CrossRef]
  247. Pandey, A.S.; Bawiskar, D.; Wagh, V. Nanocosmetics and Skin Health: A Comprehensive Review of Nanomaterials in Cosmetic Formulations. Cureus 2024, 16, e52754. [Google Scholar] [CrossRef]
  248. Fabbrocini, G.; De Vita, V.; Monfrecola, A.; De Padova, M.P.; Brazzini, B.; Teixeira, F.; Chu, A. Percutaneous collagen induction: An effective and safe treatment for post-acne scarring in different skin phototypes. J. Dermatol. Treat. 2014, 25, 147–152. [Google Scholar] [CrossRef]
  249. Lim, S.H.; Kathuria, H.; Amir, M.H.B.; Zhang, X.; Duong, H.T.; Ho, P.C.L.; Kang, L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J. Control. Release 2021, 329, 907–918. [Google Scholar] [CrossRef] [PubMed]
  250. Avcil, M.; Akman, G.; Klokkers, J.; Jeong, D.; Çelik, A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J. Cosmet. Dermatol. 2020, 19, 328–337. [Google Scholar] [CrossRef]
  251. Zhang, R.; Liu, F.; Tian, Y.; Cao, W.; Wang, R. Editorial: Nanotechnology in Traditional Medicines and Natural Products. Front. Chem. 2021, 9, 633419. [Google Scholar] [CrossRef]
  252. Chakraborty, N.; Narayanan, V.; Gautam, H.K. Nano-Therapeutics to Treat Acne Vulgaris. Indian J. Microbiol. 2022, 62, 167–174. [Google Scholar] [CrossRef]
  253. Artounian, K.; Bundogji, N.; Hoss, E.; Boen, M. Applications of Gold and Silver Nanoparticles in the Treatment of Acne Vulgaris: A Systematic Review. J. Drugs Dermatol. 2021, 20, 666–670. [Google Scholar] [PubMed]
  254. Kotla, N.; Chandrasekar, B.; Rooney, P.; Sivaraman, G.; Larrañaga, A.; Kanala, V.K.; Pandi, A.; Rochev, Y. Biomimetic Lipid-Based Nanosystems for Enhanced Dermal Delivery of Drugs and Bioactive Agents. ACS Biomater. Sci. Eng. 2017, 3, 1262–1272. [Google Scholar] [CrossRef] [PubMed]
  255. Izhar, M.P.; Hafeez, A.; Kushwaha, P.; Simrah. Drug delivery through niosomes: A comprehensive review with therapeutic applications. J. Clust. Sci. 2023, 34, 2257–2273. [Google Scholar] [CrossRef]
  256. Sangboonruang, S.; Semakul, N.; Obeid, M.A.; Ruano, M.; Kitidee, K.; Anukool, U.; Pringproa, K.; Chantawannakul, P.; Ferro, V.A.; Tragoolpua, Y.; et al. Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate Staphylococcus aureus and Staphylococcal Skin Infection. Int. J. Nanomed. 2021, 16, 7639–7661. [Google Scholar] [CrossRef]
  257. Yousefpoor, Y.; Amani, A.; Divsalar, A.; Mousavi, S.E.; Shakeri, A.; Sabzevari, J.T. Anti-rheumatic activity of topical nanoemulsion containing bee venom in rats. Eur. J. Pharm. Biopharm. 2022, 172, 168–176. [Google Scholar] [CrossRef]
  258. Du, G.; He, P.; Zhao, J.; He, C.; Jiang, M.; Zhang, Z.; Zhang, Z.; Sun, X. Polymeric microneedle-mediated transdermal delivery of melittin for rheumatoid arthritis treatment. J. Control. Release 2021, 336, 537–548. [Google Scholar] [CrossRef]
  259. Lee, H.J.; Kwon, H.K.; Kim, H.S.; Kim, M.I.; Park, H.J. Hair Growth Promoting Effect of 4HGF Encapsulated with PGA Nanoparticles (PGA-4HGF) by β-Catenin Activation and Its Related Cell Cycle Molecules. Int. J. Mol. Sci. 2019, 20, 3447. [Google Scholar] [CrossRef]
  260. Park, H.-J.; Zhang, N.; Park, D.K. Topical application of Polygonum multiflorum extract induces hair growth of resting hair follicles through upregulating Shh and β-catenin expression in C57BL/6 mice. J. Ethnopharmacol. 2011, 135, 369–375. [Google Scholar] [CrossRef]
  261. Li, Y.; Han, M.; Lin, P.; He, Y.; Yu, J.; Zhao, R. Hair growth promotion activity and its mechanism of Polygonum multiflorum. Evidence-Based Complement. Altern. Med. 2015, 2015, 517901. [Google Scholar] [CrossRef]
  262. Burnett, C.L.; Bergfeld, W.F.; Belsito, D.V.; Klaassen, C.D.; Marks, J.G.; Shank, R.C.; Slaga, T.J.; Snyder, P.W.; Andersen, F.A. Final report on the safety assessment of Cocos nucifera (coconut) oil and related ingredients. Int. J. Toxicol. 2011, 30, 5S–16S. [Google Scholar] [CrossRef]
  263. Kappally, S.; Shirwaikar, A.; Shirwaikar, A. Coconut oil–a review of potential applications. Hygeia J. Drugs Med. 2015, 7, 34–41. [Google Scholar] [CrossRef]
  264. Park, H.-J.; Han, E.S.; Park, D.K.; Lee, C.; Lee, K.W. An extract of Phellinus linteus grown on germinated brown rice inhibits inflammation markers in RAW264. 7 macrophages by suppressing inflammatory cytokines, chemokines, and mediators and up-regulating antioxidant activity. J. Med. Food 2010, 13, 1468–1477. [Google Scholar] [CrossRef]
  265. Han, E.S.; Oh, J.Y.; Park, H.-J. Cordyceps militaris extract suppresses dextran sodium sulfate-induced acute colitis in mice and production of inflammatory mediators from macrophages and mast cells. J. Ethnopharmacol. 2011, 134, 703–710. [Google Scholar] [CrossRef]
  266. Park, D.K.; Park, H.-J. Ethanol extract of Cordyceps militaris grown on germinated soybeans attenuates dextran-sodium-sulfate-(DSS-) induced colitis by suppressing the expression of matrix metalloproteinases and inflammatory mediators. Biomed. Res. Int. 2013, 2013, 102918. [Google Scholar] [CrossRef] [PubMed]
  267. Turkoglu, M.; Pekmezci, E.; Kilic, S.; Dundar, C.; Sevinc, H. Effect of Ficus carica leaf extract on the gene expression of selected factors in HaCaT cells. J. Cosmet. Dermatol. 2017, 16, e54–e58. [Google Scholar] [CrossRef] [PubMed]
  268. Patzelt, A.; Richter, H.; Knorr, F.; Schäfer, U.; Lehr, C.-M.; Dähne, L.; Sterry, W.; Lademann, J. Selective follicular targeting by modification of the particle sizes. J. Control. Release. 2011, 150, 45–48. [Google Scholar] [CrossRef]
  269. Wosicka, H.; Cal, K. Targeting to the hair follicles: Current status and potential. J. Dermatol. Sci. 2010, 57, 83–89. [Google Scholar] [CrossRef]
  270. El-Sayed, S.M.; El-Naggar, M.E.; Hussein, J.; Medhat, D.; El-Banna, M. Effect of Ficus carica L. leaves extract loaded gold nanoparticles against cisplatin-induced acute kidney injury. Colloids Surf. B Biointerfaces 2019, 184, 110465. [Google Scholar] [CrossRef]
  271. Jacob, S.P.; Prasad, V.; Sivasankar, S.; Muralidharan, P. Biosynthesis of silver nanoparticles using dried fruit extract of Ficus carica-Screening for its anticancer activity and toxicity in animal models. Food Chem. Toxicol. 2017, 109, 951–956. [Google Scholar] [CrossRef]
  272. Sumathra, M.; Rajan, M.; AmarnathPraphakar, R.; Marraiki, N.; Elgorban, A.M. In VivoAssessment of a Hydroxyapatite/κ-Carrageenan-Maleic Anhydride-Casein/DoxorubicinComposite-CoatedTitanium Bone Implant. ACS Biomater. Sci. Eng. 2020, 6, 1650–1662. [Google Scholar] [CrossRef]
  273. Rajwade, J.M.; Paknikar, K.M.; Kumbhar, J.V. Applications of bacterialcelluloseanditscomposites in biomedicine. Appl. Microbiol. Biotechnol. 2015, 99, 2491–2511. [Google Scholar] [CrossRef] [PubMed]
  274. Feng, J.; Niu, Y.; Zhang, Y.; Zuo, H.; Wang, S.; Liu, X. Ficus carica extract impregnated amphiphilic polymer scaffold for diabetic wound tissue regenerations. Artif. Cells Nanomed. Biotechnol. 2021, 49, 219–229. [Google Scholar] [CrossRef] [PubMed]
  275. Battistin, M.; Dissette, V.; Bonetto, A.; Durini, E.; Manfredini, S.; Marcomini, A.; Casagrande, E.; Brunetta, A.; Ziosi, P.; Molesini, S.; et al. A New Approach to UV Protection by Direct Surface Functionalization of TiO2 with the Antioxidant Polyphenol Dihydroxyphenyl Benzimidazole Carboxylic Acid. Nanomaterials 2020, 10, 231. [Google Scholar] [CrossRef] [PubMed]
  276. Hossein-nezhad, A.; Holick, M.F. Vitamin D for health: A global perspective. Mayo Clin. Proc. 2013, 88, 720–755. [Google Scholar] [CrossRef] [PubMed]
  277. Matsumura, Y.; Ananthaswamy, H.N. Toxic effects of ultraviolet radiation on the skin. Toxicol. Appl. Pharmacol. 2004, 195, 298–308. [Google Scholar] [CrossRef]
  278. He, H.; Li, A.; Li, S.; Tang, J.; Li, L.; Xiong, L. Natural components in sunscreens: Topical formulations with sun protection factor (SPF). Biomed. Pharmacother. 2021, 134, 111161. [Google Scholar] [CrossRef]
  279. Borase, H.P.; Patil, C.D.; Suryawanshi, R.K.; Patil, S.V. Ficus carica latex-mediated synthesis of silver nanoparticles and its application as a chemophotoprotective agent. Appl. Biochem. Biotechnol. 2013, 171, 676–688. [Google Scholar] [CrossRef]
Figure 1. Skin conditions in which bee venom formulations can be used.
Figure 1. Skin conditions in which bee venom formulations can be used.
Cosmetics 11 00195 g001
Figure 2. Skin conditions in which CV formulations can be used.
Figure 2. Skin conditions in which CV formulations can be used.
Cosmetics 11 00195 g002
Figure 3. Skin conditions in which formulations with Ficus carica can be used.
Figure 3. Skin conditions in which formulations with Ficus carica can be used.
Cosmetics 11 00195 g003
Table 1. The main components of BV and their pharmacological actions.
Table 1. The main components of BV and their pharmacological actions.
ComponentsPharmacological ActionsReferences
MelittinAnti-inflammatory, anti-bacterial, antiviral, analgesic, anti-cancer, neuroprotective.[23,24,25,26,27,28]
ApaminAnti-fungal, antiviral, anti-inflammatory, analgesic.[25,29]
Phospholipase A2Anti-inflammatory, anti-protozoal, anti-cancer, immunomodulatory.[30,31,32,33]
HyaluronidaseHydrolysis of hyaluronic acid.[34]
AdolapinAnti-inflammatory, analgesic, antipyretic.[13,22,29,35]
The peptide of mast cell degranulation (MCD)Anti-inflammatory.[36,37]
HistaminePermeability of blood vessels.[38]
Table 2. The main components of CV and their pharmacological actions.
Table 2. The main components of CV and their pharmacological actions.
ComponentsPharmacological ActionsReferences
CobratoxinAnalgesic, anti-inflammatory, anticonvulsant, antivirals[82,83,84,85,86]
CardiotoxinsCardioprotective, anti-cancer[87,88]
Phospholipase A2 (PLA2)Anticoagulant, neuroprotective, antibacterial[89,90,91,92]
Cobra venom factor (CVF)Immunosuppressive[93,94]
Nerve growth factor
(NGF)
Neuroprotective, immunomodulators[95]
L-amino Acid Oxidaze (LAAO)Anti-cancer[96,97]
Table 3. The main phytochemicals in Ficus carica and their effects on the skin.
Table 3. The main phytochemicals in Ficus carica and their effects on the skin.
Phytochemical SubstancesEffectsReference
MyricetinReduces sebum secretion[196,197]
LuteolinAnti-inflammatory, anti-allergic, eczema treatment[198,199]
QuercetinAnti-inflammatory, anti-allergic, eczema treatment,
reduces sebum secretion
[196,197,199]
KaempherolReduces sebum secretion[150]
Gallic acidReduces transdermal water loss, reduces melanin secretion, reduces sebum secretion[196,197]
Syringic acidReduces transdermal water loss, reduces melanin secretion, reduces sebum secretion[150,196,197]
FicinAntioxidant activity
Preserves the integrity of the skin, prevents premature aging, reduces oxidative stress
[200,201,202]
Vitamin CStimulation and acceleration of collagen synthesis in the dermis, antioxidant action
Reduction of transdermal water loss, hydration of the dermis, stimulation of collagen synthesis, decrease of sebum secretion
Anti-wrinkle and anti-acne effect
[150,203]
CatechinesReduces melanin secretion, reduces transdermal water loss
Antioxidant effect
[150,204]
EpicatechinAntioxidant effect
Reduces melanin secretion, reduces transdermal water loss
[150,204]
Chlorogenic acidReduces melanin secretion[150]
Table 4. Common characteristics and synergistic potential of using BV, CV and Ficus carica for skin care.
Table 4. Common characteristics and synergistic potential of using BV, CV and Ficus carica for skin care.
Common CharacteristicsBVCVFicus caricaSynergistic Potential
Anti-inflammatory propertiesMelittin, apamin, decrease inflammation [40,41].Neurotoxins inhibit inflammation [84,101].Phenolic compounds
have an anti-inflammatory effect [216,217].
The combination could effectively reduce skin irritation and inflammation by providing a complex anti-inflammatory treatment.
Antioxidant propertiesAntioxidant compounds neutralize free radicals [64].Protection against oxidative stress [104].Phenolic compounds
with antioxidant role [150].
Together, they could provide amplified antioxidant protection, preventing skin damage caused by free radicals.
Immunomodulators propertiesStimulation of immune response [65,66].Immune system modulation [107].Bioactive compounds support skin immunity
[195].
The potential to balance and regulate the skin’s immune responses, reducing the risk of infections and chronic inflammation.
Cosmetic propertiesSkin regeneration and hydration [186].
Anti-wrinkle [182].
Lifting effect and
anti-wrinkle [190].
Regeneration [191].
Regeneration [219,220].
Hydration [150,203].
Antirid [150].
The potential to create a complex formula that regenerates, hydrates, and prevents wrinkles.
Safety in useDose-influenced safety and individual sensitivity
[19,226,227].
Variable safety depending on dose and method of administration
[107,231].
Generally favorable safety profile [151,233,234,235,236].Improved safety and optimized efficiency, with reduced risks of irritation and side effects.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dinu, M.; Galea, C.; Chirilov, A.M.; Tatu, A.L.; Nwabudike, L.C.; Dumitriu Buzia, O.; Stefan, C.S. A Journey Along the Boulevard of Bioactive Compounds from Natural Sources, with Cosmetic and Pharmaceutical Potential: Bee Venom, Cobra Venom, Ficus carica. Cosmetics 2024, 11, 195. https://doi.org/10.3390/cosmetics11060195

AMA Style

Dinu M, Galea C, Chirilov AM, Tatu AL, Nwabudike LC, Dumitriu Buzia O, Stefan CS. A Journey Along the Boulevard of Bioactive Compounds from Natural Sources, with Cosmetic and Pharmaceutical Potential: Bee Venom, Cobra Venom, Ficus carica. Cosmetics. 2024; 11(6):195. https://doi.org/10.3390/cosmetics11060195

Chicago/Turabian Style

Dinu, Monica, Carmen Galea, Ana Maria Chirilov, Alin Laurențiu Tatu, Lawrence Chukwudi Nwabudike, Olimpia Dumitriu Buzia, and Claudia Simona Stefan. 2024. "A Journey Along the Boulevard of Bioactive Compounds from Natural Sources, with Cosmetic and Pharmaceutical Potential: Bee Venom, Cobra Venom, Ficus carica" Cosmetics 11, no. 6: 195. https://doi.org/10.3390/cosmetics11060195

APA Style

Dinu, M., Galea, C., Chirilov, A. M., Tatu, A. L., Nwabudike, L. C., Dumitriu Buzia, O., & Stefan, C. S. (2024). A Journey Along the Boulevard of Bioactive Compounds from Natural Sources, with Cosmetic and Pharmaceutical Potential: Bee Venom, Cobra Venom, Ficus carica. Cosmetics, 11(6), 195. https://doi.org/10.3390/cosmetics11060195

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop